download.lww.comdownload.lww.com/wolterskluwer_vitalstream_com/PermaLink/... · Web...

1

International Clinical Psychopharmacology 2015Bandelow B. et al., Efficacy of Treatments for Anxiety Disorders – A Meta-Analysis

Supplementary Digital Content (Online only)

Contains:

Methods: Use of scales if the HAMA or LSAS were not available Abbreviations Table: Studies included in the meta-analysis References for studies included in the meta-analysis

Use of scales if the HAMA or LSAS were not available

We used for PDA (1) a panic-specific scale such as the Panic and Agoraphobia Scale (PAS) (1) or the Panic Disorder Severity Scale (PDSS) (2); if not available: (2) the CGI (Clinical Global Impression Scale) (3); if not available: (3) a measure of panic attack frequency; if not available: (4) other measures. For GAD, we used alternatively: (1) the Penn State Worry Questionnaire (PWSQ) (4); if not available: the (2) the CGI; if not available: (3) other measures. For SAD, we used (1) a symptom-specific scale like the Brief Social Phobia Scale (BSPS) (5), the Social Phobia Scale (SPS) (6); the Social Interaction Anxiety Scale (SIAS) (6) or others; if not available: (2) the CGI; if not available: (3) other measures.

Abbreviations

AR Applied RelaxationBAI Beck Anxiety InventoryBSPS Brief Social Phobia ScaleCBT Cognitive-Behavioural Therapy/ExposureCBT + group Cognitive/Exposure Therapy combined with drug treatmentCGI Clinical Global ImpressionCI 95% confidence intervalDSM Diagnostic and Statistical Manual for Mental DisordersEMDR Eye Movement Desensitization ReprocessingFQ-SP Fear Questionnaire–Social Phobia GAD Generalised anxiety disorderHAMA Hamilton Rating Scale for AnxietyIPT Interpersonal TherapyITT Intention to treatLSAS Liebowitz Social Anxiety ScaleLOCF Last observation carried forwardMAOI Irreversible monoamine oxidase inhibitorNS Not significantPAS Panic and Agoraphobia ScalePDA Panic Disorder/AgoraphobiaPDSS Panic Disorder Severity ScalePDTh Psychodynamic TherapyPGI Patients’ Global ImpressionPMR Progressive Muscle RelaxationPSWQ Penn State Worry QuestionnaireRIMA Reversible inhibitor of monoamine oxidase ASAD Social Anxiety DisorderSADS Social Avoidance and Distress ScaleSD Standard deviationSE Standard error of the meanSIAS Social Interaction Anxiety ScaleSNRIs Serotonin-noradrenaline reuptake inhibitors

2

SPS Social Phobia ScaleSSRIs Selective serotonin reuptake inhibitors

3

Studies included in the meta-analysis

Table: Studies used in the meta-analysis. Two papers (7, 8) contained two studies each. Disorder: PDA, panic disorder/agoraphobia; GAD, generalised anxiety disorder; SAD, social anxiety disorder; d, Cohen’s d (pre-post); N, post-treatment sample sizes (ITT); duration, study duration in weeks; ITT, intent-to-treat analysis. Other abbreviations: Table 1.

No Arm

No Study

Authors, Year, Treatment Ref. Disorder

Treatment Treatment Group Outcome d N Dura-tion/

weeks

ITT

1 1 Abramowitz et al. 2009 Biblio (9) SAD Bibliotherapy Non-Face-to-Face Therapy BSPS 1.278 11 8 no2 Abramowitz et al. 2009 WL SAD Waitlist Waitlist BSPS 0.402 10 8 no3 2 Addis et al., 2004 CBT (10) PDA CBT CBT PDSS 0.870 38 24 yes4 3 Allgulander et al., 1999 PAR (11) SAD Paroxetine SSRIs LSAS 1.517 44 13 yes5 Allgulander et al., 1999 PLA SAD Pill Placebo Pill Placebo LSAS 0.391 48 13 yes6 4 Allgulander, Dahl et al., 2004 PLA (12) GAD Pill Placebo Pill Placebo HAMA 1.695 189 12 yes7 Allgulander, Dahl et al., 2004 SER GAD Sertraline SSRIs HAMA 2.478 184 12 yes8 5 Allgulander, Mangano et al., 2004 PAR (13) SAD Paroxetine SSRIs LSAS 1.884 128 12 yes9 Allgulander, Mangano et al., 2004 PLA SAD Pill Placebo Pill Placebo LSAS 1.017 132 12 yes

10 Allgulander, Mangano et al., 2004 VLX SAD Venlafaxine SNRIs LSAS 1.916 129 12 yes11 6 Andersson et al., 2012 iCBT (14) GAD Internet-CBT Non-Face-to-Face Therapy PSWQ 1.184 23 13 yes12 Andersson et al., 2012 iPDTh GAD Internet-PDTh Non-Face-to-Face Therapy PSWQ 1.309 26 13 yes13 Andersson et al., 2012 WL GAD Waitlist Waitlist PSWQ 0.939 26 13 yes14 7 Andrews et al., 2011 CBT (15) SAD CBT CBT SPS 0.744 11 8 yes15 Andrews et al., 2011 iCBT SAD Internet-CBT Non-Face-to-Face Therapy SPS 0.675 14 8 yes16 8 Arntz & van den Hout, 1996 AR (16) PDA Applied Relaxation Relaxation Panic Frequency 0.530 18 12 no17 Arntz & van den Hout, 1996 CBT PDA CBT CBT Panic Frequency 1.270 18 12 no18 Arntz & van den Hout, 1996 WL PDA Waitlist Waitlist Panic Frequency 0.020 18 12 no19 9 Arntz, 2003 AR (17) GAD Applied Relaxation Relaxation STAI 0.527 17 12 yes20 Arntz, 2003 CBT GAD CBT CBT STAI 0.520 20 12 yes21 10 Asakura et al., 2007 FLV (18) SAD Fluvoxamine SSRIs LSAS 1.592 176 10 yes22 Asakura et al., 2007 PLA SAD Pill Placebo SSRIs LSAS 1.152 89 10 yes23 11 Asnis et al., 2001 FLV (19) PDA Fluvoxamine SSRIs Panic Disorder

severity1.531 87 8 yes

4

24 Asnis et al., 2001 PLA PDA Pill Placebo Pill Placebo Panic Disorder severity

0.919 92 8 yes

25 12 Bakker et al. 1999 CBT (20) PDA CBT CBT HAMA 1.084 35 12 yes26 Bakker et al. 1999 CMI PDA Clomipramine TCAs HAMA 1.189 32 12 yes27 Bakker et al. 1999 PAR PDA Paroxetine SSRIs HAMA 1.750 32 12 yes28 Bakker et al. 1999 PLA PDA Pill Placebo Pill Placebo HAMA 0.627 35 12 yes29 13 Baldwin et al., 1999 PAR (21) SAD Paroxetine SSRIs LSAS 1.336 139 12 yes30 Baldwin et al., 1999 PLA SAD Pill Placebo Pill Placebo LSAS 0.709 151 12 yes31 14 Baldwin et al., 2006 Esc (22) GAD Escitalopram SSRIs HAMA 3.588 403 12 yes32 Baldwin et al., 2006 PAR GAD Paroxetine SSRIs HAMA 3.336 139 12 yes33 Baldwin et al., 2006 PLA GAD Pill Placebo Pill Placebo HAMA 3.220 139 12 yes34 15 Ball et al., 2005 PAR (23) GAD Paroxetine SSRIs HAMA 4.056 25 8 yes35 Ball et al., 2005 SER GAD Sertraline SSRIs HAMA 4.080 28 8 yes36 16 Ballenger et al., 1988 ALZ (24) PDA Alprazolam Benzodiazepines N panic attacks 0.574 247 3 yes37 Ballenger et al., 1988 PLA PDA Pill Placebo Pill Placebo N panic attacks 0.267 234 3 yes38 17 Ballenger et al., 1998 PAR (25) PDA Paroxetine SSRIs HAMA 1.147 209 10 yes39 Ballenger et al., 1998 PLA PDA Pill Placebo Pill Placebo HAMA 0.901 69 10 yes40 18 Bandelow et al., 2004 PAR (26) PDA Paroxetine SSRIs HAMA 2.030 81 12 yes41 Bandelow et al., 2004 SER PDA Sertraline SSRIs HAMA 2.061 85 12 yes42 Bandelow et al., 2010 PAR (27) GAD Paroxetine SSRIs HAMA 3.438 214 8 yes43 19 Bandelow et al., 2010 PLA GAD Pill Placebo Pill Placebo HAMA 2.926 217 8 yes44 Bandelow et al., 2010 QUE GAD Quetiapine Quetiapine HAMA 3.558 435 8 yes45 20 Barlow et al., 1989 CBT (28) PDA CBT CBT HAMA 1.396 15 15 no46 Barlow et al., 1989 CBT+PMR PDA CBT + PMR CBT + Relaxation HAMA 1.576 16 15 no47 Barlow et al., 1989 PMR PDA PMR Relaxation HAMA 2.334 10 15 no48 Barlow et al., 1989 WL PDA Waitlist Waitlist HAMA 0.419 15 15 no49 21 Barlow et al., 1992 CBT+PMR (29) GAD CBT + PMR CBT + Relaxation HAMA 1.332 11 15 yes50 Barlow et al., 1992 CT+RLX GAD CT + Relaxation CBT HAMA 1.332 10 15 yes51 Barlow et al., 1992 PMR GAD PMR Relaxation HAMA 1.432 10 15 yes52 Barlow et al., 1992 WL GAD Waitlist Waitlist HAMA -0.783 12 15 yes53 22 Barlow et al., 2000 CBT (30) PDA CBT CBT PDSS 1.269 56 13 yes54 Barlow et al., 2000 CBT+IMI PDA CBT + Imipramine CBT + Drug PDSS 1.828 47 13 yes55 Barlow et al., 2000 CBT+PLA PDA CBT + Pill Placebo CBT + Pill Placebo PDSS 1.399 45 13 yes

5

56 Barlow et al., 2000 IMI PDA Imipramine TCAs PDSS 1.549 51 13 yes57 Barlow et al., 2000 PLA PDA Pill Placebo Pill Placebo PDSS 0.634 14 13 yes58 23 Beauclair et al., 1994 CLZ (31) PDA Clonazepam Benzodiazepines CGI-S 5.875 12 4 yes59 Beauclair et al., 1994 PLA PDA Pill Placebo Pill Placebo CGI-S 0.750 8 4 yes60 24 Beck et al., 1992 CBT (32) PDA CBT CBT Panic Attacks per

week1.008 14 8 no

61 Beck et al., 1992 PP PDA Psychological Placebo Psychological Placebo Panic Attacks per week

0.269 15 8 no

62 25 Beck et al., 1994 CBT (33) PDA CBT CBT HAMA 0.522 17 10 no63 Beck et al., 1994 Relax PDA Relaxation Relaxation HAMA 1.181 19 10 no64 Beck et al., 1994 WL PDA Waitlist Waitlist HAMA -0.349 22 10 no65 26 Berger et al., 2009 iCBT (34) SAD Internet-CBT Non-Face-to-Face Therapy LSAS 0.820 31 10 yes66 Berger et al., 2009 WL SAD Waitlist Waitlist LSAS 0.200 21 10 yes67 27 Berger et al., 2011 iCBT (35) SAD iCBT Non-Face-to-Face Therapy LSAS 0.803 27 10 yes68 28 Bergstrom et al., 2010 CBTG (36) PDA CBT Group CBT Group PDSS 1.833 44 10 no69 Bergstrom et al., 2010 iCBT PDA iCBT Non-Face-to-Face Therapy PDSS 1.881 44 10 no70 29 Beutel et al., 2013 HAMA CBT (37) PDA CBT CBT HAMA 1.550 14 12 no71 Beutel et al., 2013 HAMA PDTh PDA PDTh PDTh HAMA 0.880 29 12 no72 30 Bielski et al. , 2005 ESC (38) GAD Escitalopram SSRIs HAMA 4.315 60 24 yes73 Bielski et al. , 2005 PAR GAD Paroxetine SSRIs HAMA 3.694 61 24 yes74 31 Black et al. 1993 CBT (39) PDA CBT CBT Clinical Anxiety

Scale1.012 25 8 yes

75 Black et al. 1993 FLV PDA Fluvoxamine SSRIs Clinical Anxiety Scale

2.285 25 8 yes

76 Black et al. 1993 PLA PDA Pill Placebo Pill Placebo Clinical Anxiety Scale

0.987 25 8 yes

77 32 Blanco et al., 2010 CBT+PHE (40) SAD CBT Group + Phenelzine CBT + Drug LSAS 1.592 32 12 yes78 Blanco et al., 2010 CBTG SAD CBT Group CBT Group LSAS 0.575 34 12 yes79 Blanco et al., 2010 PHE SAD Phenelzine Phenelzine LSAS 1.288 35 12 yes80 Blanco et al., 2010 PLA SAD Pill Placebo Pill Placebo LSAS 0.505 27 12 yes81 33 Blomhoff et al., 2001 EXP (41) SAD Exposure CBT CGI-S 1.000 91 24 yes82 Blomhoff et al., 2001 PLA SAD Pill Placebo Pill Placebo CGI-S 1.000 88 24 yes83 Blomhoff et al., 2001 SER SAD Sertraline SSRIs CGI-S 1.273 87 24 yes84 Blomhoff et al., 2001 SER+EXP SAD Sertraline + Exposure CBT + Drug CGI-S 1.413 88 24 yes85 34 Boettcher et al, 2012 iCBT (42) SAD Internet-CBT Non-Face-to-Face Therapy LSAS 1.382 34 10 yes

6

86 Boettcher et al, 2012 iCBT-I SAD Internet-CBT-i Non-Face-to-Face Therapy LSAS 1.740 34 10 yes87 35 Bohni et al., 2009 CBT (43) PDA CBT CBT BAI 1.040 20 13 no88 Bohni et al., 2009 CBT-M PDA CBT-massed CBT BAI 0.980 19 3 no89 36 Borge et al, 2008 CBT (44) SAD CBT CBT SPAI 0.916 40 10 yes90 Borge et al, 2008 IPT SAD IPT IPT SPAI 0.929 39 10 yes91 37 Borgeat et al., 2009 et al. CBTG (45) SAD CBT Group CBT Group LSAS 1.104 14 8 no92 Borgeat et al., 2009 et al. CBTG ex SAD CBT Group + EXP CBT Group LSAS 1.300 13 8 no93 38 Borkovec et al., 1987 CBT+PMR (46) GAD CBT + PMR CBT HAMA 1.831 37 12 no94 Borkovec et al., 1987 NT+PMR GAD nondirective therapy +

PMRPsychological Placebo HAMA 1.421 14 12 no

95 39 Borkovec et al., 1993 AR (47) GAD Applied Relaxation Relaxation HAMA 1.872 18 6 no96 Borkovec et al., 1993 CBT GAD CBT CBT PSWQ 1.814 16 6 no97 Borkovec et al., 1993 NT GAD nondirective therapy Psychological Placebo HAMA 1.181 13 6 no98 40 Borkovec et al., 2002 AR (48) GAD Applied Relaxation Relaxation HAMA 2.249 18 14 yes99 Borkovec et al., 2002 CBT GAD CBT CBT PSWQ 2.309 21 14 yes

100 41 Bouchard et al., 1996 CBT (49) PDA CBT CBT STAI 0.514 14 30 no101 Bouchard et al., 1996 EXP PDA Exposure CBT STAI 1.085 14 30 no102 42 Boyer et al., 1993 DIA (50) GAD Diazepam Benzodiazepines HAMA 2.345 47 4 no103 Boyer et al., 1993 PLA GAD Pill Placebo Pill Placebo HAMA 1.318 42 4 no104 43 Bradwejn et al., 2005 PLA (51) PDA Pill Placebo Pill Placebo CGI-S 2.914 168 10 yes105 Bradwejn et al., 2005 VLX PDA Venlafaxine SNRIs CGI-S 3.653 160 10 yes106 44 Brawman-Mintzer et al., 2006 PLA (52) GAD Pill Placebo Pill Placebo HAMA 3.762 162 10 yes107 Brawman-Mintzer et al., 2006 SER GAD Sertraline SSRIs HAMA 4.288 164 10 yes108 45 Broocks et al., 1998 HAMA CMI (53) PDA Clomipramine TCAs HAMA 1.929 15 10 yes109 Broocks et al., 1998 HAMA EXE PDA Exercise Exercise HAMA 1.777 16 10 yes110 Broocks et al., 1998 HAMA PLA PDA Pill Placebo Pill Placebo HAMA 0.262 15 10 yes111 46 Brown et al., 1997 CBT (54) PDA CBT CBT HAMA 1.419 19 15 no112 Brown et al., 1997 CBT-f PDA CBT CBT HAMA 1.017 21 15 no113 47 Butler, 1991 CBT (55) GAD CBT CBT HAMA 2.312 19 7 no114 Butler, 1991 CBT wo AM GAD CBT ohne AM CBT HAMA 0.843 18 7 no115 Butler, 1991 WL GAD Waitlist Waitlist HAMA 0.598 19 7 no116 48 Bystritsky et al., 1994 DES (56) PDA Desipramine TCAs HAMA 1.227 10 10 no117 Bystritsky et al., 1994 FLX PDA Fluoxetine SSRIs HAMA 2.301 11 10 no

7

118 49 Caillard et al., 1999 CMI (57) PDA Clomipramine TCAs HAMA 4.102 107 8 yes119 Caillard et al., 1999 PLA PDA Pill Placebo Pill Placebo HAMA 3.240 51 8 yes120 50 Carlbring et al., 2005 CBT (58) PDA CBT CBT BAI 1.179 24 10 yes121 Carlbring et al., 2005 iCBT PDA iCBT Non-Face-to-Face Therapy BAI 0.754 25 10 yes122 51 Carlbring et al., 2006 iCBT (59) PDA Internet-CBT Non-Face-to-Face Therapy BAI 1.267 28 10 yes123 Carlbring et al., 2006 WL PDA Waitlist Waitlist BAI -0.010 29 10 yes124 52 Carlbring et al., 2007 iCBT (60) SAD Internet-CBT Non-Face-to-Face Therapy LSAS 1.096 29 9 yes125 Carlbring et al., 2007 WL SAD Waitlist Waitlist LSAS -0.060 28 9 yes126 53 Castillo et al., 1987 ALZ (61) GAD Alprazolam Benzodiazepines HAMA 1.860 31 8 yes127 Castillo et al., 1987 CLB GAD Clobazam Benzodiazepines HAMA 1.589 32 8 yes128 Castillo et al., 1987 PLA GAD Pill Placebo Pill Placebo HAMA 1.473 33 8 yes129 54 Clark et al., 1994 AR (62) PDA Applied Relaxation Relaxation Panic/Anxiety

composite score1.557 20 12 yes

130 Clark et al., 1994 CBT PDA CBT CBT Panic/anxiety composite score

2.470 20 12 yes

131 Clark et al., 1994 IMI PDA Imipramine TCAs Panic/anxiety composite score

2.216 20 12 yes

132 55 Clark et al., 1999 CBT (63) PDA CBT CBT BAI 1.669 14 12 no133 Clark et al., 1999 CBT brief PDA CBT brief CBT BAI 1.491 14 12 no134 Clark et al., 1999 WL PDA Waitlist Waitlist BAI 0.237 14 12 no135 56 Clark et al., 2003 CBT (64) SAD CBT CBT LSAS 1.830 20 16 yes136 Clark et al., 2003 FLX SAD Fluoxetine SSRIs LSAS 0.812 19 16 yes137 Clark et al., 2003 PLA SAD Pill Placebo + Self

ExposurePill Placebo LSAS 0.665 20 16 yes

138 57 Clark et al., 2006 CBT (65) SAD CBT CBT LSAS 1.978 21 14 yes139 Clark et al., 2006 EXP-AR SAD Exposure + Applied

RelaxationCBT LSAS 1.125 21 14 yes

140 Clark et al., 2006 WL SAD Waitlist Waitlist LSAS -0.001 20 14 yes141 58 CNCPS 1992 Deltito et al., 1991 ALZ (66) PDA Alprazolam Benzodiazepines HAMA 1.608 386 8 yes142 CNCPS 1992 Deltito et al., 1991 IMI PDA Imipramine TCAs HAMA 1.712 391 8 yes143 CNCPS 1992 Deltito et al., 1991 PLA PDA Pill Placebo Pill Placebo HAMA 1.505 391 8 yes144 59 Cottraux et al. 1995 CBT+BUS (67) PDA CBT + Buspirone CBT + Drug PPGA Agoraphobia 1.659 21 16 yes145 Cottraux et al. 1995 CBT+PLA PDA CBT + Pill Placebo CBT + Pill Placebo PPGA Agoraphobia 1.903 27 16 yes146 60 Cottraux et al., 2000 CBT (68) SAD CBT CBT LSAS 0.699 27 12 no147 Cottraux et al., 2000 PP SAD Psychological Placebo Psychological Placebo LSAS 0.204 28 12 no

8

148 61 Craske et al., 1995 CBT (69) PDA CBT CBT Panic frequency 0.791 16 4 no149 Craske et al., 1995 PP PDA Psychological Placebo Psychological Placebo Panic frequency 0.180 13 4 no150 62 Craske et al., 2003 CBT (70) PDA CBT CBT Panic frequency 1.004 27 16 no151 Craske et al., 2003 CBT+EXP PDA CBT + EXP CBT Panic frequency 0.587 26 16 no152 63 Crits-Christoph et al., 2011 CBT+Drug (71) GAD CBT + Drug CBT + Drug HAMA 7.299 17 24 no153 Crits-Christoph et al., 2011 VLX GAD Venlafaxine SNRIs HAMA 7.675 24 24 no154 64 Cutler et al., 1993 LOR (72) GAD Lorazepam Benzodiazepines HAMA 2.465 82 4 yes155 Cutler et al., 1993 PLA GAD Pill Placebo Pill Placebo HAMA 2.079 76 4 yes156 65 Darcis et al, 1995 PLA (73) GAD Pill Placebo Pill Placebo HAMA 1.462 56 5 no157 Darcis et al., 1995 HYD GAD Hydroxyzine Hydroxyzine HAMA 2.726 54 5 no158 66 Davidson et al., 1993 CLZ (74) SAD Clonazepam Benzodiazepines LSAS 1.621 39 10 yes159 Davidson et al., 1993 PLA SAD Pill Placebo Pill Placebo LSAS 0.637 36 10 yes160 67 Davidson et al., 1999 BUS (75) GAD Buspirone Buspirone HAMA 0.834 93 8 yes161 Davidson et al., 1999 PLA GAD Pill Placebo Pill Placebo HAMA 0.704 98 8 yes162 Davidson et al., 1999 VLX GAD Venlafaxine SNRIs HAMA 0.924 174 8 yes163 68 Davidson, Bose et al. 2004 ESC (76) GAD Escitalopram SSRIs HAMA 2.539 154 8 yes164 Davidson, Bose et al. 2004 PLA GAD Pill Placebo Pill Placebo HAMA 1.663 153 8 yes165 69 Davidson, Foa et al., 2004 CBT+FLX (77) SAD CBT + Fluoxetine CBT + Drug BSPS 1.808 59 14 yes166 Davidson, Foa et al., 2004 CBT+PLA SAD CBT + Pill Placebo CBT + Pill Placebo BSPS 1.767 59 14 yes167 Davidson, Foa et al., 2004 CBTG SAD CBT Group CBT Group BSPS 1.921 60 14 yes168 Davidson, Foa et al., 2004 FLX SAD Fluoxetine SSRIs BSPS 1.818 57 14 yes169 Davidson, Foa et al., 2004 PLA SAD Pill Placebo Pill Placebo BSPS 1.095 60 14 yes170 70 Davidson, Yaryura et al. 2004 FLV (78) SAD Fluvoxamine SSRIs LSAS 1.476 139 12 yes171 Davidson, Yaryura et al. 2004 PLA SAD Pill Placebo Pill Placebo LSAS 0.713 140 12 yes172 71 de Beurs et al. 1995 EXP (79) PDA Exposure alone CBT Agoraphobic

composite1.545 18 12 yes

173 de Beurs et al. 1995 FLX+EXP PDA Fluvoxamine + Exposure CBT + Drug Agoraphobic composite

2.667 19 12 yes

174 de Beurs et al. 1995 PLA PDA Pill Placebo + Exposure CBT + Pill Placebo Agoraphobic composite

1.230 19 12 yes

175 de Beurs et al. 1995 PME PDA Panic Management + Exposure

CBT Agoraphobic composite

1.261 20 12 yes

176 72 Den Boer et al., 1990 FLV (80) PDA Fluvoxamine SSRIs FQ agoraphobia 1.713 20 8 no177 Den Boer et al., 1990 PLA PDA Pill Placebo Pill Placebo FQ agoraphobia 0.135 19 8 no

9

178 73 Dugas et al., 2003 CBTG (81) GAD CBT Group CBT Group PSWQ 1.625 23 14 no179 Dugas et al., 2003 WL GAD Waitlist Waitlist PSWQ 0.263 25 14 no180 74 Dugas et al., 2010 AR (82) GAD Applied Relaxation Relaxation PSWQ 0.841 31 12 no181 Dugas et al., 2010 CBT GAD CBT CBT PSWQ 1.199 33 12 no182 Dugas et al., 2010 WL GAD Waitlist Waitlist PSWQ -0.176 19 12 no183 75 Dunner et al., 1986 APZ (83) PDA Alprazolam Benzodiazepines HAMA 1.317 13 7 no184 Dunner et al., 1986 DIA PDA Diazepam Benzodiazepines HAMA 1.329 13 7 no185 Dunner et al., 1986 PLA PDA Pill Placebo Pill Placebo HAMA 1.179 14 7 no186 76 Elie & Lamontagne, 1984 ALP (84) GAD Alprazolam Benzodiazepines HAMA 4.157 24 4 no187 Elie & Lamontagne, 1984 DIA GAD Diazepam Benzodiazepines HAMA 4.377 24 4 no188 77 Enkelmann, 1991 ALZ (85) GAD Alprazolam Benzodiazepines PGI 2.547 28 6 no189 Enkelmann, 1991 BUS GAD Buspirone Buspirone PGI 2.017 20 6 no190 Enkelmann, 1991 PLA GAD Pill Placebo Pill Placebo PGI 0.628 10 6 no191 78 Fahy et al., 1992 CMI (86) PDA CBT + Clomipramine CBT + Drug HAMA 2.605 18 6 no192 Fahy et al., 1992 PLA PDA Pill Placebo Pill Placebo HAMA 1.695 24 6 no193 79 Feltner et al., 2003 LOR (87) GAD Lorazepam Benzodiazepines HAMA 2.704 64 4 yes194 Feltner et al., 2003 PLA GAD Pill Placebo Pill Placebo HAMA 2.885 66 4 yes195 78 Feltner et al., 2003 PRG GAD Pregabalin Pregabalin HAMA 2.786 130 4 yes196 80 Feltner et al., 2011 PLA (88) SAD Pill Placebo Pill Placebo LSAS 0.962 82 11 yes197 Feltner et al., 2011 PRG SAD Pregabalin Pregabalin LSAS 1.229 246 11 yes198 81 Ferreri et al., 1994 HYD (89) GAD Hydroxyzine Hydroxyzine HAMA 1.682 41 4 no199 Ferreri et al., 1994 PLA GAD Pill Placebo Pill Placebo HAMA 0.954 41 4 no200 82 Feske & Goldstein, 1997 EMDR (90) PDA EMDR EMDR BAI 1.197 15 6 no201 Feske & Goldstein, 1997 WL PDA Waitlist Waitlist BAI 0.124 15 6 no202 83 Fonseca D'El Rey et al., 2008 CBTG (91) SAD CBT Group CBT Group SPIN 1.795 15 12 no203 Fonseca D'El Rey et al., 2008 WL SAD Waitlist Waitlist SPIN 0.071 16 12 no204 84 Fontaine et al., 1983 BRO (92) GAD Bromazepam Benzodiazepines HAMA 2.907 16 4 no205 Fontaine et al., 1983 DIA GAD Diazepam Benzodiazepines HAMA 2.558 16 4 no206 Fontaine et al., 1983 PLA GAD Pill Placebo Pill Placebo HAMA 0.581 16 4 no207 85 Fontaine et al., 1986 BRO (93) GAD Bromazepam Benzodiazepines HAMA 2.829 20 4 yes208 Fontaine et al., 1986 LOR GAD Lorazepam Benzodiazepines HAMA 2.481 20 4 yes209 82 Fontaine et al., 1986 PLA GAD Pill Placebo Pill Placebo HAMA 1.318 20 4 yes

10

210 86 Furmark et al., 2009 Study 1 Bib (7) SAD Bibliotherapy Waitlist LSAS 0.848 40 9 no211 Furmark et al., 2009 Study 1 iCBT SAD Internet-CBT Clinician-

AssNon-Face-to-Face Therapy LSAS 0.854 40 9 no

212 Furmark et al., 2009 Study 1 WL SAD Waitlist Waitlist LSAS 0.043 40 9 no213 87 Furmark et al., 2009 Study 2 Bib (7) SAD Bibliotherapy Non-Face-to-Face Therapy LSAS 0.835 29 9 no214 Furmark et al., 2009 Study 2 BibD SAD Bibliotherapy +

Discussion GroupNon-Face-to-Face Therapy LSAS 1.308 28 9 no

215 Furmark et al., 2009 Study 2 iAR SAD Internet-AR Non-Face-to-Face Therapy LSAS 1.063 29 9 no216 Furmark et al., 2009 Study 2 iCBT SAD Internet-CBT Clinician-

AssNon-Face-to-Face Therapy LSAS 1.220 29 9 no

217 88 Gelenberg et al., 2000 PLA (94) GAD Pill Placebo Pill Placebo HAMA 1.740 123 28 yes218 Gelenberg et al., 2000 VLX GAD Venlafaxine SNRIs HAMA 2.680 115 28 yes219 89 Gelernter et al., 1991 ALZ (95) SAD Alprazolam Benzodiazepines SAD 1.232 12 12 yes220 Gelernter et al., 1991 CBT SAD CBT Group CBT Group SAD 0.752 17 12 yes221 Gelernter et al., 1991 PHE SAD Phenelzine Phenelzine SAD 1.035 13 12 yes222 Gelernter et al., 1991 PLA SAD Pill Placebo Pill Placebo SAD 0.863 15 12 yes223 90 Gloster et al., 2011 HAMA CBT (96) PDA CBT CBT HAMA 1.926 242 26 yes224 Gloster et al., 2011 HAMA WL PDA Waitlist Waitlist HAMA 0.342 64 26 yes225 92 Goldstein et al., 2000 I EMDR (8) PDA EMDR EMDR PDSS 0.773 14 4 no226 Goldstein et al., 2000 I WL PDA Waitlist Waitlist PDSS -0.005 13 4 no227 93 Goldstein et al., 2000 II EMDR (8) PDA EMDR EMDR PDSS 0.768 6 4 no228 Goldstein et al., 2000 II PP PDA Psychological Placebo Psychological Placebo PDSS -0.005 7 4 no229 94 Gruber et al., 2001 CBTG (97) SAD CBT Group CBT Group SPS 0.805 14 12 yes230 Gruber et al., 2001 CBTG + SAD CBT Group + Handheld CBT SPS 0.420 15 8 yes231 Gruber et al., 2001 WL SAD Waitlist Waitlist SPS 0.100 17 12 yes232 95 Hackett et al., 2003 DIA (98) GAD Diazepam Benzodiazepines HAMA 2.868 89 8 yes233 Hackett et al., 2003 PLA GAD Pill Placebo Pill Placebo HAMA 2.267 97 8 yes234 Hackett et al., 2003 VLX GAD Venlafaxine SNRIs HAMA 2.608 345 8 yes235 96 Hartford et al., 2007 DLX (99) GAD Duloxetine SNRIs HAMA 2.087 162 10 yes236 Hartford et al., 2007 PLA GAD Pill Placebo Pill Placebo HAMA 1.626 161 10 yes237 Hartford et al., 2007 VLX GAD Venlafaxine SNRIs HAMA 2.194 164 10 yes238 97 Hayes-Skelton et al., 2013 (100) GAD Applied Relaxation Relaxation HAMA 1.212 81 16 yes239 Hayes-Skelton et al., 2013 ABBT GAD ABBT CBT HAMA 1.115 81 16 yes240 98 Hedman et al., 2011 CBT (101) SAD CBT CBT LSAS 1.066 50 15 yes

11

241 Hedman et al., 2011 iCBT SAD Internet-CBT Non-Face-to-Face Therapy LSAS 1.321 51 15 yes242 99 Heimberg et al., 1990 CBT (102) SAD CBT Group CBT Group FQ Social Phobia 1.063 20 12 no243 Heimberg et al., 1990 PP SAD Psychological Placebo Psychological Placebo FQ Social Phobia 0.766 20 12 no244 100 Heimberg et al., 1998 CBT (103) SAD CBT Group CBT Group LSAS anxiety

subscale0.427 28 12 yes

245 Heimberg et al., 1998 PHE SAD Phenelzine Phenelzine LSAS anxiety subscale

1.228 26 12 yes

246 Heimberg et al., 1998 PLA SAD Pill Placebo Pill Placebo LSAS anxiety subscale

0.448 27 12 yes

247 Heimberg et al., 1998 PP SAD Psychological Placebo Psychological Placebo LSAS anxiety subscale

0.008 26 12 yes

248 101 Hofmann et al., 2004 CBTG (104) SAD CBT Group CBT Group SPAI 0.720 12 12 no249 Hofmann et al., 2004 EXP SAD Exposure CBT SPAI 0.520 18 12 no250 102 Hoge et al., 2013 MIND (105) GAD Mindfulness Mindfulness HAMA 1.163 48 8 yes251 Hoge et al., 2013 PP GAD Psychological Placebo Psychological Placebo HAMA 0.871 41 8 yes252 103 Hope et al., 1995 CBTG (106) SAD CBT Group CBT Group FQ-SP 0.914 13 12 no253 Hope et al., 1995 EXP SAD Exposure CBT FQ-SP 1.207 10 12 no254 Hope et al., 1995 WL SAD Waitlist Waitlist FQ-SP -0.241 10 12 no255 104 Hovland et al., 2012 CBT (107) PDA CBT CBT BAI 1.151 19 12 yes256 Hovland et al., 2012 EXE PDA Exercise Exercise BAI 0.604 17 12 yes257 105 Hoyer et al., 2009 CBT (108) GAD CBT CBT HAMA 1.307 29 15 yes258 Hoyer et al., 2009 REL GAD Applied Relaxation Relaxation HAMA 1.459 28 15 yes259 Hoyer et al., 2009 WL GAD Waitlist Waitlist HAMA 0.303 29 15 yes260 106 IMCTGMSP, 1997 MOC (109) SAD Moclobemide Moclobemide LSAS 1.123 384 12 yes261 IMCTGMSP, 1997 PLA SAD Pill Placebo Pill Placebo LSAS 0.811 194 12 yes262 107 Ito et al., 2001 EXP (110) PDA Exposure i CBT HAMA 1.610 57 10 no263 Ito et al., 2001 WL PDA Waitlist Waitlist HAMA -0.013 18 10 no264 108 Jazaieri et al., 2012 EXE (111) SAD Exercise Exercise LSAS 1.382 28 8 yes265 Jazaieri et al., 2012 MIND SAD Mindfulness Mindfulness LSAS 1.666 24 8 yes266 109 Kasper et al., 2005 ESC (112) SAD Escitalopram SSRIs LSAS 2.033 181 12 yes267 Kasper et al., 2005 PLA SAD Pill Placebo Pill Placebo LSAS 1.603 177 12 yes268 110 Kasper et al., 2009 PLA (113) GAD Pill Placebo Pill Placebo HAMA 1.884 128 8 yes269 Kasper et al., 2009 PRG GAD Pregabalin Pregabalin HAMA 2.335 121 8 yes270 Kasper et al., 2009 VLX GAD Venlafaxine SNRIs HAMA 1.932 125 8 yes

12

271 111 Kenardy et al., 2003 CBT (114) PDA CBT CBT STAI 1.254 120 9 yes272 Kenardy et al., 2003 WL PDA Waitlist Waitlist STAI 0.096 41 12 yes273 112 Khan et al., 2011 PLA (115) GAD Pill Placebo Pill Placebo HAMA 2.958 225 8 yes274 Khan et al., 2011 QUE GAD Quetiapine Quetiapine HAMA 3.439 669 8 yes275 113 Kiropoulos et al., 2008 CBT (116) PDA CBT CBT PDSS 1.182 35 12 yes276 Kiropoulos et al., 2008 iCBT PDA iCBT Non-Face-to-Face Therapy PDSS 1.048 35 12 yes277 114 Klosko et al., 1990 ALZ (117) PDA Alprazolam Benzodiazepines HAMA 0.921 16 15 yes278 Klosko et al., 1990 CBT PDA CBT CBT HAMA 1.296 15 15 yes279 Klosko et al., 1990 PLA PDA Pill Placebo Pill Placebo HAMA 0.727 11 15 yes280 Klosko et al., 1990 WL PDA Waitlist Waitlist HAMA 0.327 15 15 yes281 115 Knijnik et al., 2004 PDTh (118) SAD PDTh PDTh LSAS 0.962 15 12 no282 Knijnik et al., 2004 PP SAD Psychological Placebo Psychological Placebo LSAS 0.405 15 12 no283 116 Knijnik et al., 2008 CLZ (119) SAD Clonazepam Benzodiazepines LSAS 0.709 28 12 no284 117 Kobak et al., 2002 FLX (120) SAD Fluoxetine SSRIs LSAS 1.138 15 8 yes285 Kobak et al., 2002 PLA SAD Pill Placebo Pill Placebo LSAS 1.176 15 8 yes286 118 Kocovski et al., 2013 CBT (121) SAD CBT CBT LSAS 1.650 32 12 no287 Kocovski et al., 2013 Mind SAD Mindfulness Mindfulness LSAS 1.652 37 12 no288 Kocovski et al., 2013 WL SAD Waitlist Waitlist LSAS 0.639 32 12 no289 119 Koponen et al., 2007 DLX (122) GAD Duloxetine SNRIs HAMA 1.719 338 9 yes290 Koponen et al., 2007 PLA GAD Pill Placebo Pill Placebo HAMA 1.139 175 9 yes291 120 Koszycki et al., 2007 CBT (123) SAD CBT Group CBT Group LSAS 2.409 27 12 yes292 Koszycki et al., 2007 Mind SAD Mindfulness Mindfulness LSAS 1.984 26 12 yes293 121 Krüger & Dahl 1999, CMI (124) PDA Clomipramine TCAs HAMA 0.943 53 8 yes294 Krüger & Dahl, 1999 MOC PDA Moclobemide Moclobemide HAMA 0.770 50 8 yes295 122 Lader & Scotto, 1998 BUS (125) GAD Buspirone Buspirone HAMA 2.091 82 4 yes296 Lader & Scotto, 1998 HYD GAD Hydroxyzine Hydroxyzine HAMA 2.566 81 4 yes297 Lader & Scotto, 1998 PLA GAD Pill Placebo Pill Placebo HAMA 1.711 82 4 yes298 123 Lader et al., 2004 ESC (126) SAD Escitalopram SSRIs LSAS 2.473 354 24 yes299 Lader et al., 2004 PAR SAD Paroxetine SSRIs LSAS 2.413 124 24 yes300 Lader et al., 2004 PLA SAD Pill Placebo Pill Placebo LSAS 1.972 116 24 yes301 124 Ladouceur et al., 2000 CBT (127) GAD CBT CBT BAI 1.073 14 16 no302 Ladouceur et al., 2000 WL GAD Waitlist Waitlist BAI 0.247 12 16 no

13

303 125 Lecrubier et al., 1997 CMI (128) PDA Clomipramine TCAs Response HAMA 3.056 121 12 no304 Lecrubier et al., 1997 PAR PDA Paroxetine SSRIs Response HAMA 3.139 119 12 no305 Lecrubier et al., 1997 PLA PDA Pill Placebo Pill Placebo Response HAMA 2.701 122 12 no306 126 Leichsenring et al., 2009 CBT (129) GAD CBT CBT HAMA 2.583 29 30 yes307 Leichsenring et al., 2009 PDTh GAD PDTh PDTh HAMA 2.105 28 30 yes308 127 Leichsenring et al., 2013 CBT (130) SAD CBT CBT LSAS 1.320 209 37,4 yes309 Leichsenring et al., 2013 PDTh SAD PDTh PDTh LSAS 1.022 207 38,7 yes310 Leichsenring et al., 2013 WL SAD Waitlist Waitlist LSAS 0.235 79 29 yes311 128 Lepola et al., 2004 PAR (131) SAD Paroxetine SSRIs LSAS 1.297 185 12 yes312 Lepola et al., 2004 PLA SAD Pill Placebo Pill Placebo LSAS 0.752 184 12 yes313 129 Lidren et al., 1994 Biblio (132) PDA Bibliotherapy Non-Face-to-Face Therapy panic frequency 1.603 11 8 no314 Lidren et al., 1994 CBTG PDA CBT Group CBT Group panic frequency 1.740 11 8 no315 Lidren et al., 1994 WL PDA Waitlist Waitlist panic frequency 0.242 11 8 no316 130 Liebowitz et al., 1988 PHE (133) SAD Phenelzine Phenelzine CGI-S 1.700 14 4 no317 Liebowitz et al., 1988 PLA SAD Pill Placebo Pill Placebo CGI-S 0.200 14 4 no318 131 Liebowitz et al., 1992 PHE (134) SAD Phenelzine Phenelzine LSAS 1.080 25 4 0319 Liebowitz et al., 1992 PLA SAD Pill Placebo Pill Placebo LSAS 0.218 26 4 Bla

nk320 132 Liebowitz et al., 2002 PAR (135) SAD Paroxetine SSRIs LSAS 1.180 175 12 yes321 Liebowitz et al., 2002 PLA SAD Pill Placebo Pill Placebo LSAS 0.655 67 12 yes322 133 Liebowitz et al., 2003 PLA (136) SAD Pill Placebo Pill Placebo LSAS 1.361 204 12 yes323 Liebowitz et al., 2003 SER SAD Sertraline SSRIs LSAS 1.945 211 12 yes324 134 Liebowitz et al., 2009 PLA (137) PDA Pill Placebo Pill Placebo PDSS 1.453 150 10 yes325 Liebowitz et al., 2009 VLX PDA Venlafaxine SNRIs PDSS 1.798 140 10 yes326 135 Liebowitz, Gelenberg et al., 2005 PLA (138) SAD Pill Placebo Pill Placebo LSAS 1.129 146 12 yes327 Liebowitz, Gelenberg et al., 2005 PAR SAD Paroxetine SSRIs LSAS 1.994 142 12 yes328 Liebowitz, Gelenberg et al., 2005 VLX SAD Venlafaxine SNRIs LSAS 1.780 141 12 yes329 136 Liebowitz, Mangano et al., 2005 PLA (139) SAD Pill Placebo Pill Placebo LSAS 0.921 138 12 yes330 Liebowitz, Mangano et al., 2005 VLX SAD Venlafaxine SNRIs LSAS 1.556 133 12 yes331 137 Linden et al., 2005 CBT (140) GAD CBT CBT HAMA 1.145 29 25 no332 Linden et al., 2005 WL GAD Waitlist Waitlist HAMA 0.181 32 25 no333 138 Lindsay et al., 1987 BZ (141) SAD Benzodiazepines Benzodiazepines GHQ 2.437 10 4 no334 Lindsay et al., 1987 CBT SAD CBT CBT GHQ 3.866 10 4 no

14

335 Lindsay et al., 1987 PP SAD Anxiety Management Psychological Placebo GHQ 2.941 10 4 no336 Lindsay et al., 1987 WL SAD Waitlist Waitlist GHQ 0.420 10 4 no337 139 Lipsitz et al., 2008 IPT (142) SAD IPT IPT LSAS 0.848 26 14 yes338 Lipsitz et al., 2008 PP SAD PDTh-Supportive Psychological Placebo LSAS 0.600 26 14 yes339 140 Llorca et al., 2002 HYD (143) GAD Hydroxyzine Hydroxyzine HAMA 3.260 96 12 yes340 Llorca et al., 2002 PLA GAD Pill Placebo Pill Placebo HAMA 2.529 100 12 yes341 141 Loerch et al. 1999 CBT+PLA (144) PDA CBT + Pill Placebo CBT + Pill Placebo FQ 1.720 13 8 yes342 Loerch et al. 1999 MOC PDA Moclobemide + Clinical

ManagementMoclobemide FQ 0.571 9 8 yes

343 Loerch et al. 1999 MOC+CBT PDA Moclobemide + CBT CBT + Drug FQ 1.273 11 8 yes344 Loerch et al. 1999 PLA PDA Pill Placebo + Clinical

ManagementPill Placebo + Psychological Placebo

FQ 0.829 9 8 yes

345 142 Londborg et al., 1998 PLA (145) PDA Pill Placebo Pill Placebo N Panic attacks 0.558 31 12 yes346 Londborg et al., 1998 SER PDA Sertraline SSRIs N Panic attacks 0.402 83 12 yes347 143 Lydiard et al., 1992 ALP (146) PDA Alprazolam Benzodiazepines Panic frequency 0.520 61 6 yes348 Lydiard et al., 1992 PLA PDA Pill Placebo Pill Placebo Panic frequency 0.271 33 6 yes349 144 Marchand et al., 2009 CBT (147) PDA CBT CBT Anxiety Sensitivity

Index1.308 84 14 yes

350 145 Marks et al., 1993 CBT+PLA (148) PDA Pill Placebo + Exposure CBT + Pill Placebo N panic attacks 0.828 30 8 no351 Marks et al., 1993 PLA+RLX PDA Pill Placebo + Relaxation Pill Placebo + Relaxation N panic attacks 0.558 31 8 no352 Marks, et al., 1993 CBT+ALZ PDA Alprazolam + Exposure CBT + Drug N panic attacks 0.732 34 8 no353 146 Mavissakalian et al., 1986b CBT (149) PDA Exposure + Pill Placebo CBT Zung Anxiety Scale 1.101 16 12 no354 Mavissakalian et al., 1986b IMI PDA Imipramine +

Psychological PlaceboTCAs Zung Anxiety Scale 1.619 16 12 no

355 Mavissakalian et al., 1986b IMI+EXP PDA Imipramine + Exposure CBT + Drug Zung Anxiety Scale 1.683 13 12 no356 Mavissakalian et al., 1986b PLA PDA Pill Placebo +

Psychological PlaceboPill Placebo + Psychological Placebo

Zung Anxiety Scale 0.734 11 12 no

357 147 Merideth et al., 2012 ESC (150) GAD Escitalopram SSRIs HAMA 2.974 203 8 yes358 Merideth et al., 2012 PLA GAD Pill Placebo Pill Placebo HAMA 2.598 203 8 yes359 Merideth et al., 2012 QUE GAD Quetiapine Quetiapine HAMA 3.180 413 8 yes360 148 Mersch et al., 1995 EXP (151) SAD Exposure CBT FQ-SP 0.761 13 14 no361 Mersch et al., 1995 WL SAD Waitlist CBT FQ-SP 0.131 17 14 no362 149 Michelson et al., 1988 EXP (152) PDA Exposure CBT Zung Anxiety Scale 1.188 22 10 no363 Michelson et al., 1988 Para PDA Paradoxical Intention CBT Zung Anxiety Scale 1.348 26 12 no364 Michelson et al., 1988 RLX PDA Relaxation Relaxation Zung Anxiety Scale 1.518 25 10 no

15

365 150 Michelson et al., 1998 FLX (153) PDA Fluoxetine SSRIs HAMA 1.087 153 10 yes366 Michelson et al., 1998 PLA PDA Pill Placebo Pill Placebo HAMA 0.725 74 10 yes367 151 Milrod et al., 2007 HAMA AR (154) PDA Applied Relaxation Relaxation HAMA 0.755 15 12 yes368 Milrod et al., 2007 HAMA PDTh PDA PDTh PDTh HAMA 1.093 24 12 yes369 152 Möller et al., 2001 ALZ (155) GAD Alprazolam Benzodiazepines HAMA 2.086 102 4 yes370 Möller et al., 2001 OPI GAD Opipramol TCAs HAMA 1.990 100 4 yes371 Möller et al., 2001 PLA GAD Pill Placebo Pill Placebo HAMA 1.786 105 4 yes372 153 Montgomery et al., 2006 PLA (156) GAD Pill Placebo Pill Placebo HAMA 2.398 100 6 yes373 Montgomery et al., 2006 PRG GAD Pregabalin Pregabalin HAMA 2.977 198 6 yes374 Montgomery et al., 2006 VLX GAD Venlafaxine SNRIs HAMA 3.039 110 6 yes375 154 Moroz & Rosenbaum, 1999 CLZ (157) PDA Clonazepam Benzodiazepines HAMA 1.284 222 6 yes376 Moroz & Rosenbaum, 1999 PLA PDA Pill Placebo Pill Placebo HAMA 0.778 216 6 yes377 155 Mörtberg et al., 2007 CBT (158) SAD CBT CBT LSAS 1.396 28 17 yes378 Mörtberg et al., 2007 CBTG SAD CBT Group CBT Group LSAS 0.714 26 17 yes379 156 Nair et al., 1996 FLX (159) PDA Fluvoxamine SSRIs CAS 1.126 50 8 yes380 Nair et al., 1996 IMI PDA Imipramine TCAs CAS 1.818 48 8 yes381 Nair et al., 1996 PLA PDA Pill Placebo Pill Placebo CAS 0.922 50 8 yes382 157 Newman, 2011 CBT+SL (160) GAD CBT + Supportive

listeningCBT HAMA 1.620 34 14 yes

383 Newman, 2011 CBT+IPT GAD CBT + IPT CBT + IPT HAMA 2.022 34 14 yes384 158 Nicolini et al., 2008 DLX (161) GAD Duloxetine SNRIs HAMA 2.069 242 10 yes385 Nicolini et al., 2008 PLA GAD Pill Placebo Pill Placebo HAMA 1.535 170 10 yes386 Nicolini et al., 2008 VLX GAD Venlafaxine SNRIs HAMA 2.096 169 10 yes387 159 Nimatoudis, 2004 PLA (162) GAD Pill Placebo Pill Placebo HAMA 1.921 22 8 yes388 Nimatoudis, 2004 VLX GAD Venlafaxine SNRIs HAMA 3.416 24 8 yes389 160 Nordin et al., 2010 Biblio (163) PDA Bibliotherapy Non-Face-to-Face Therapy PDSS 2.322 20 10 1390 Nordin et al., 2010 WL PDA Waitlist Waitlist PDSS 0.322 20 10 Bla

nk391 161 Noyes et al., 1984 (164) PDA Diazepam Benzodiazepines HAMA 1.495 21 2 no392 162 Oehrberg et al., 1995 PAR (165) PDA Paroxetine SSRIs Response HAMA 3.545 60 12 yes393 Oehrberg et al., 1995 PLA PDA Pill Placebo Pill Placebo Response HAMA 2.607 60 12 yes394 163 Oosterbaan et al., 2001 CBT (166) SAD CBT CBT LSAS anxiety


395 Oosterbaan et al., 2001 MOC SAD Moclobemide Moclobemide LSAS anxiety 0.390 24 15 yes

16

subscale396 Oosterbaan et al., 2001 PLA SAD Pill Placebo Pill Placebo LSAS anxiety


397 164 Öst & Breitholtz, 2000 AR (167) GAD Applied Relaxation Relaxation HAMA 1.959 18 12 no398 Öst & Breitholtz, 2000 CBT GAD CBT CBT HAMA 1.900 15 12 no399 165 Öst & Westling, 1995 AR (168) PDA Applied Relaxation Relaxation HAMA 3.054 18 12 no400 Öst & Westling, 1995 CBT PDA CBT CBT HAMA 2.494 18 12 no401 166 Öst et al., 1993 AR (169) PDA Applied Relaxation Relaxation FQ 1.259 15 12 no402 Öst et al., 1993 CBT PDA CBT CBT FQ 1.018 15 12 no403 Öst et al., 1993 EXP PDA Exposure CBT FQ 1.032 15 12 no404 167 Öst et al., 2004 CBT (170) PDA CBT CBT HAMA 1.436 26 14 yes405 Öst et al., 2004 EXP PDA Exposure CBT HAMA 1.128 25 14 yes406 Öst et al., 2004 WL PDA Waitlist Waitlist HAMA 0.322 20 14 yes407 168 Pande et al., 2003 LOR (171) GAD Lorazepam Benzodiazepines HAMA 3.768 68 4 yes408 Pande et al., 2003 PLA GAD Pill Placebo Pill Placebo HAMA 2.107 69 4 yes409 Pande et al., 2003 PRG GAD Pregabalin Pregabalin HAMA 3.035 139 4 yes410 169 Pande et al., 2004 PLA (172) SAD Pill Placebo Pill Placebo LSAS 0.826 46 10 yes411 Pande et al., 2004 PRG SAD Pregabalin Pregabalin LSAS 1.203 89 10 yes412 170 Paxling et al., 2011 iCBT (173) GAD Internet-CBT Clinician-

AssNon-Face-to-Face Therapy PSWQ 1.076 45 8 yes

413 Paxling et al., 2011 WL GAD Waitlist Waitlist PSWQ -0.010 44 8 yes414 171 Petracca et al., 1990 BUS (174) GAD Buspirone Buspirone HAMA 2.633 15 8 no415 Petracca et al., 1990 LOR GAD Lorazepam Benzodiazepines HAMA 1.814 18 8 no416 172 Pohl et al., 2005 PLA (175) GAD Pill Placebo Pill Placebo HAMA 1.240 61 6 yes417 Pohl et al., 2005 PRG GAD Pregabalin Pregabalin HAMA 1.704 185 6 yes418 174 Pollack et al., 1996 PLA (176) PDA Pill Placebo Pill Placebo HAMA -0.007 12 8 yes419 Pollack et al., 1996 VLX PDA Venlafaxine SNRIs HAMA 0.709 13 8 yes420 175 Pollack et al., 1998 PLA (177) PDA Pill Placebo Pill Placebo HAMA 1.871 87 10 yes421 Pollack et al., 1998 SER PDA Sertraline SSRIs HAMA 2.136 88 10 yes422 176 Pollack et al., 2001 PAR (178) GAD Paroxetine SSRIs HAMA 3.090 161 8 yes423 Pollack et al., 2001 PLA GAD Pill Placebo Pill Placebo HAMA 2.488 163 8 yes424 177 Pollack, Lepola et al., 2007 PAR (179) PDA Paroxetine SSRIs CGI-S 3.086 166 12 yes425 Pollack, Lepola et al., 2007 PLA PDA Pill Placebo Pill Placebo CGI-S 2.026 156 12 yes

17

426 Pollack, Lepola et al., 2007 VLX PDA Venlafaxine SNRIs CGI-S 3.013 317 12 yes427 178 Pollack, Mangano et al., 2007 PAR (180) PDA Paroxetine SNRIs Response CGI-I 2.967 151 12 yes428 Pollack, Mangano et al., 2007 PLA PDA Pill Placebo Pill Placebo Response CGI-I 3.095 157 12 yes429 Pollack, Mangano et al., 2007 VLX PDA Venlafaxine SNRIs Response CGI-I 2.934 316 12 yes430 179 Pols et al., 1993 FLV (181) PDA Fluvoxamine SSRIs N Panic

attacks/week0.361 18 4 no

431 Pols et al., 1993 PLA PDA Pill Placebo Pill Placebo Number of panic attacks per week

0.000 18 4 no

432 180 Power et al., 1989 CBT (182) GAD CBT CBT HAMA 2.987 10 6 no433 Power et al., 1989 DIA GAD Diazepam Benzodiazepines HAMA 1.962 10 6 no434 Power et al., 1989 PLA GAD Pill Placebo Pill Placebo HAMA 0.894 11 6 no435 181 Power et al., 1990 CBT (183) GAD CBT CBT Anxiety Rating 3.853 21 10 no436 Power et al., 1990 CBT+PLA GAD CBT + Pill Placebo CBT + Pill Placebo Anxiety Rating 2.999 18 10 no437 Power et al., 1990 DIA GAD Diazepam Benzodiazepines Anxiety Rating 2.174 22 10 no438 Power et al., 1990 DIA+CBT GAD Diazepam + CBT Benzodiazepines Anxiety Rating 4.918 21 10 no439 Power et al., 1990 PLA GAD Pill Placebo Pill Placebo Anxiety Rating 1.499 19 10 no440 182 Prasko et al., 2006 CBT+MOC (184) SAD CBT Group +

MoclobemideCBT + Drug LSAS 4.413 22 26 yes

441 Prasko et al., 2006 CBT+PLA SAD CBT Group + Pill Placebo

CBT + Pill Placebo LSAS 4.579 20 26 yes

442 Prasko et al., 2006 MOC SAD Moclobemide Moclobemide LSAS 3.555 20 26 yes443 183 Rapee et al., 2009 CBT (185) SAD CBT CBT CGI-S 1.240 59 12 yes444 Rapee et al., 2009 CBT-E SAD CBT Enhanced CBT CGI-S 1.600 68 12 yes445 Rapee et al., 2009 PP SAD Stress management Psychological Placebo CGI-S 1.100 56 12 yes446 184 Ribeiro et al., 2001 (186) PDA Fluoxetine SSRIs HAMA 2.422 13 8 yes447 185 Rickels et al., 1997 DIA (187) GAD Diazepam Benzodiazepines HAMA 3.077 67 8 yes448 Rickels et al., 1997 PLA GAD Pill Placebo Pill Placebo HAMA 1.529 65 8 yes449 186 Rickels et al., 2000 PLA (188) GAD Pill Placebo Pill Placebo HAMA 2.304 96 8 yes450 Rickels et al., 2000 VLX GAD Venlafaxine SNRIs HAMA 2.834 253 8 yes451 187 Rickels et al., 2003 PAR (189) GAD Paroxetine SSRIs HAMA 3.430 385 8 yes452 Rickels et al., 2003 PLA GAD Pill Placebo Pill Placebo HAMA 3.388 180 8 yes453 188 Rickels et al., 2005 ALZ (190) GAD Alprazolam Benzodiazepines HAMA 2.927 88 4 yes454 Rickels et al., 2005 PLA GAD Pill Placebo Pill Placebo HAMA 2.240 85 4 yes455 Rickels et al., 2005 PRG GAD Pregabalin Pregabalin HAMA 3.134 261 4 yes

18

456 189 Rickels, Mangano et al., 2004 PLA (191) SAD Pill Placebo Pill Placebo LSAS 0.352 135 12 yes457 Rickels, Mangano et al., 2004 VLX SAD Venlafaxine SNRIs LSAS 0.523 126 12 yes458 190 Robinson et al., 2010 iCBT (192) GAD Internet-CBT Clinician-

AssNon-Face-to-Face Therapy PSWQ 1.300 46 10 yes

459 Robinson et al., 2010 T GAD Internet-CBT Technician-Ass

Non-Face-to-Face Therapy PSWQ 1.121 45 10 yes

460 Robinson et al., 2010 WL GAD Waitlist Waitlist PSWQ 0.164 47 10 yes461 191 Rocca et al., 1997 DEL (193) GAD Delorazepam Benzodiazepines HAMA 3.538 20 8 no462 Rocca et al., 1997 IMI GAD Imipramine TCAs HAMA 4.168 21 8 no463 Rocca et al., 1997 PAR GAD Paroxetine SSRIs HAMA 4.678 25 8 no464 192 Roemer et al. 2008 CBT (194) GAD CBT CBT PSWQ 1.814 16 yes465 Roemer et al. 2008 WL GAD Waitlist Waitlist PSWQ 0.487 16 yes466 193 Salaberria et al., 1998 CBT (195) SAD CBT + Exposure CBT SADS 1.871 18 8 no467 Salaberria et al., 1998 EXP SAD Exposure CBT SADS 2.643 18 8 no468 Salaberria et al., 1998 WL SAD Waitlist Waitlist SADS 0.267 20 8 no469 194 Schneier et al., 1998 MOC (196) SAD Moclobemide Moclobemide LSAS 0.627 39 8 yes470 Schneier et al., 1998 PLA SAD Pill Placebo Pill Placebo LSAS 0.224 36 8 yes471 195 Schweizer et al., 1990 ALZ (197) PDA Alprazolam Benzodiazepines HAMA 1.104 24 6 yes472 Schweizer et al., 1990 LOR PDA Lorazepam Benzodiazepines HAMA 0.951 28 6 yes473 196 Sharp et al. 1997 BCT+PLA (198) PDA CBT + Pill Placebo CBT + Pill Placebo GHQ 0.826 33 13 no474 Sharp et al. 1997 CBT PDA CBT CBT GHQ 1.045 30 13 no475 Sharp et al. 1997 FLV PDA Fluvoxamine SSRIs GHQ 0.680 29 13 no476 Sharp et al. 1997 FLV+CBT PDA Fluvoxamine + CBT CBT + Drug GHQ 0.918 29 13 no477 Sharp et al. 1997 PLA PDA Pill Placebo Pill Placebo GHQ 0.205 28 13 no478 197 Sharp et al., 2000 Biblio (199) PDA Bibliotherapy Non-Face-to-Face Therapy CGI-S 0.732 29 12 no479 Sharp et al., 2000 CBT PDA CBT CBT CGI-S 2.913 29 12 no480 Sharp et al., 2000 PP PDA Psychological Placebo Psychological Placebo CGI-S 1.640 29 12 no481 198 Sharp et al., 2004 CBT (200) PDA CBT CBT HAMA 3.463 31 12 no482 Sharp et al., 2004 CBTG PDA CBT Group CBT Group HAMA 2.220 20 12 no483 Sharp et al., 2004 WL PDA Waitlist Waitlist HAMA 0.805 19 12 no484 199 Shear et al., 1994 CBT (201) PDA CBT CBT HAMA 1.131 24 15 yes485 Shear et al., 1994 PP PDA nondirective therapy Psychological Placebo HAMA 1.395 21 15 yes486 200 Sheehan et al., 1990 BUS (202) PDA Buspirone Buspirone HAMA 1.219 16 8 yes

19

487 Sheehan et al., 1990 IMI PDA Imipramine TCAs HAMA 1.543 18 8 yes488 Sheehan et al., 1990 PLA PDA Pill Placebo Pill Placebo HAMA 0.940 18 8 yes489 201 Sheehan et al., 1993 ALZ (203) PDA Alprazolam Benzodiazepines HAMA 1.335 34 8 yes490 Sheehan et al., 1993 BUS PDA Buspirone Buspirone HAMA 0.514 27 8 yes491 Sheehan et al., 1993 PLA PDA Pill Placebo Pill Placebo HAMA 0.367 31 8 yes492 202 Sheehan et al., 2005 PAR (204) PDA Paroxetine SSRIs HAMA 1.235 444 10 yes493 Sheehan et al., 2005 PLA PDA Pill Placebo Pill Placebo HAMA 0.866 445 10 yes494 203 Smits et al., 2006 AUD (205) SAD Exposure Video AUD CBT LSAS 0.451 17 4 no495 Smits et al., 2006 EXP SAD Exposure CBT LSAS 0.854 18 4 no496 Smits et al., 2006 PER SAD Exposure Video PER CBT LSAS 0.816 18 4 no497 Smits et al., 2006 PP SAD Psychological Placebo Psychological Placebo LSAS 0.412 15 4 no498 204 Sramek et al., 1996 BUS (206) GAD Buspirone Buspirone HAMA 0.408 52 6 yes499 Sramek et al., 1996 PLA GAD Pill Placebo Pill Placebo HAMA 0.331 61 6 yes500 205 Stahl et al., 2003 HAMA CIT (207) PDA Citalopram SSRIs HAMA 0.718 112 10 yes501 Stahl et al., 2003 HAMA ESC PDA Escitalopram SSRIs HAMA 0.894 125 10 yes502 Stahl et al., 2003 HAMA PLA PDA Pill Placebo Pill Placebo HAMA 0.674 114 10 yes503 206 Stangier et al., 2003 CBT (208) SAD CBT CBT SPS 0.705 50 15 yes504 Stangier et al., 2003 WL SAD Waitlist Waitlist SPS 0.155 21 15 yes505 207 Stangier et al., 2011 CBT (209) SAD CBT CBT LSAS 1.218 38 20 yes506 Stangier et al., 2011 IPT SAD IPT IPT LSAS 0.828 38 20 yes507 Stangier et al., 2011 WL SAD Waitlist Waitlist LSAS 0.117 41 20 yes508 208 Stein DJ et al., 2003 FLV (210) SAD Fluvoxamine SSRIs LSAS 2.988 56 12 yes509 Stein DJ et al., 2003 PLA SAD Pill Placebo Pill Placebo LSAS 2.690 53 12 yes510 209 Stein et al., 2005 PLA (211) GAD Pill Placebo Pill Placebo LSAS 1.084 126 26 yes511 Stein et al., 2005 VLX GAD Venlafaxine SNRIs LSAS 1.751 238 26 yes512 210 Stein MB et al., 2000 CBT+Drug (212) PDA CBT + Paroxetine CBT + Drug BAI 1.230 15 10 yes513 Stein MB et al., 2000 CBT+PLA PDA CBT + Pill Placebo CBT + Pill Placebo BAI 0.804 15 10 yes514 211 Stein, Cameron et al., 2002 MOC (213) SAD Moclobemide Moclobemide LSAS 2.190 188 12 yes515 Stein, Cameron et al., 2002 PLA SAD Pill Placebo Pill Placebo LSAS 2.472 189 12 yes516 212 Stein, MB et al., 1998 PAR (214) SAD Paroxetine SSRIs LSAS 1.370 94 12 yes517 Stein, MB et al., 1998 PLA SAD Pill Placebo Pill Placebo LSAS 0.651 93 12 yes518 213 Stein, MB et al., 1999 FLV (215) SAD Fluvoxamine SSRIs BSPS 1.210 48 12 yes

20

519 Stein, MB et al., 1999 PLA SAD Pill Placebo Pill Placebo BSPS 0.641 44 12 yes520 214 Swinson et al., 1995 Telephone CBT (216) PDA Telephone CBT Non-Face-to-Face Therapy FQ Agoraphobia 0.785 20 10 no521 Swinson et al., 1995 WL PDA Waitlist Waitlist FQ Agoraphobia 0.045 22 10 no522 215 Telch et al., 1993 CBTG (217) PDA CBT Group CBT Group SPRAS 1.593 34 8 no523 Telch et al., 1993 WL PDA Waitlist Waitlist SPRAS 0.164 33 8 no524 216 Telch et al., 1995 CBT (218) PDA CBT CBT SAS 1.202 112 9 no525 Telch et al., 1995 WL PDA Waitlist Waitlist SAS 0.401 28 9 no526 217 Tesar et al., 1991 ALZ (219) PDA Alprazolam Benzodiazepines CGI-I 1.390 20 6 no527 Tesar et al., 1991 CLZ PDA Clonazepam Benzodiazepines CGI-I 1.853 24 6 no528 Tesar et al., 1991 PLA PDA Pill Placebo Pill Placebo CGI-I 0.695 8 6 no529 218 Tiller et al., 1999 FLX (220) PDA Fluoxetine SSRIs Response CGI-I 3.829 184 8 yes530 Tiller et al., 1999 MOC PDA Moclobemide Moclobemide Response CGI-I 3.879 182 8 yes531 219 Titov et a., 2008-1 iCBT (221) SAD Internet-CBT Non-Face-to-Face Therapy Social Phobia Scale 0.860 50 10 yes532 Titov et a., 2008-1 WL SAD Waitlist Waitlist Social Phobia Scale 0.139 49 10 yes533 220 Titov et a., 2008-2 iCBT (222) SAD Internet-CBT Non-Face-to-Face Therapy Social Phobia Scale 1.062 41 10 yes534 Titov et a., 2008-2 WL SAD Waitlist Waitlist Social Phobia Scale 0.258 40 10 yes535 221 Titov et a., 2008-3 iCBT (223) SAD Internet-CBT Non-Face-to-Face Therapy Social Phobia Scale 0.270 34 10 yes536 Titov et a., 2008-3 iCBT-C SAD Internet-CBT Clinician-

AssNon-Face-to-Face Therapy Social Phobia Scale 0.944 30 10 yes

537 Titov et al., 2008-3 WL SAD Waitlist Waitlist Social Phobia Scale -0.062 30 10 yes538 222 Titov et al., 2009 iCBT (224) GAD Internet-CBT Non-Face-to-Face Therapy PSWQ 0.889 24 9 yes539 Titov et al., 2009 WL GAD Waitlist Waitlist PSWQ 0.018 19 9 yes540 223 Uhlenhuth et al., 1989 ALZ (225) PDA Alprazolam Benzodiazepines HAMA 1.246 41 8 yes541 Uhlenhuth et al., 1989 IMI PDA Imipramine TCAs HAMA 0.551 20 8 yes542 Uhlenhuth et al., 1989 PLA PDA Pill Placebo Pill Placebo HAMA 0.253 20 8 yes543 224 van Ameringen et al., 2001 PLA (226) SAD Pill Placebo Pill Placebo BSPS 1.027 69 20 yes544 van Ameringen et al., 2001 SER SAD Sertraline SSRIs BSPS 1.716 134 20 yes545 225 van Apeldoorn et al. 2008 CBT (227) PDA CBT CBT HAMA 0.622 37 39 yes546 van Apeldoorn et al. 2008 CBT+SSRI PDA CBT + SSRI CBT + Drug HAMA 1.389 36 39 yes547 van Apeldoorn et al. 2008 SSRI PDA SSRI SSRIs HAMA 0.827 27 39 yes548 226 van Vliet et al., 1994 FLV (228) SAD Fluvoxamine SSRIs LSAS 1.760 15 12 no549 van Vliet et al., 1994 PLA SAD Pill Placebo Pill Placebo LSAS 0.484 13 12 no550 227 Versiani et al. 1992 MOC (229) SAD Moclobemide Moclobemide HAMA 1.563 26 8 yes

21

551 Versiani et al. 1992 PHE SAD Phenelzine Phenelzine HAMA 2.376 26 8 yes552 Versiani et al. 1992 PLA SAD Pill Placebo Pill Placebo HAMA 0.735 26 8 yes553 228 Vos et al., 2012 CBT (230) PDA CBT CBT Panic Attack

Frequency0.564 48 13 yes

554 Vos et al., 2012 IPT PDA IPT IPT Panic Attack Frequency

0.564 43 13 yes

555 229 Wade et al., 1997 CIT (231) PDA Citalopram SSRIs HAMA 1.385 281 8 yes556 Wade et al., 1997 CMI PDA Clomipramine TCAs HAMA 1.492 98 8 yes557 Wade et al., 1997 PLA PDA Pill Placebo Pill Placebo HAMA 0.960 96 8 yes558 230 Wells, 2010 AR (232) GAD Applied Relaxation Relaxation PSWQ 0.811 10 10 no559 Wells, 2010 CBT GAD CBT CBT PSWQ 3.828 10 10 no560 231 Westenberg et al., 2004 FLV (233) SAD Fluvoxamine SSRIs LSAS 1.802 146 12 yes561 Westenberg et al., 2004 PLA SAD Pill Placebo Pill Placebo LSAS 1.363 148 12 yes562 232 Wiborg et al., 1996 CMI (234) PDA Clomipramine TCAs HAMA 1.418 18 39 no563 Williams & Falbo, 1996 CBT (235) PDA Exposure CBT FQ phobia 0.961 39 8 no564 Williams & Falbo, 1996 WL PDA Waitlist Waitlist FQ phobia 0.244 9 8 no565 233 Wims et al., 2010 iCBT (236) PDA Internet-CBT Non-Face-to-Face Therapy PDSS 1.051 19 8 yes566 Wims et al., 2010 WL PDA Waitlist Waitlist PDSS 0.186 25 8 yes567 234 Woelk et al., 2010 LOR (237) GAD Lorazepam Benzodiazepines HAMA 2.900 37 6 yes

22

References for studies included in the meta-analysis

1. Bandelow B: Panic and Agoraphobia Scale (PAS): Manual. Seattle, Hogrefe & Huber Pub., 1999

2. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA: Multicenter collaborative panic disorder severity scale. Am J Psychiatry 1997; 154(11):1571-5

3. Guy W: Clinical Global Impression Scale (CGI). ECDEU Assessment Manual for Psychopharmacology. Washington, D.C., National Institute of Mental Health-US Dept of Health, Education, and Welfare publication (ADM), 1976, pp 76-338

4. Meyer TJ, Miller ML, Metzger RL, Borkovec TD: Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 1990; 28(6):487-95

5. Davidson JR, Miner CM, De Veaugh-Geiss J, Tupler LA, Colket JT, Potts NL: The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 1997; 27(1):161-6

6. Mattick RP, Clarke JC: Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998; 36(4):455-70

7. Furmark T, Carlbring P, Hedman E, Sonnenstein A, Clevberger P, Bohman B, Eriksson A, Hallen A, Frykman M, Holmstrom A, Sparthan E, Tillfors M, Ihrfelt EN, Spak M, Ekselius L, Andersson G: Guided and unguided self-help for social anxiety disorder: randomised controlled trial. Br J Psychiatry 2009; 195(5):440-7

8. Goldstein AJ, de Beurs E, Chambless DL, Wilson KA: EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditions. J Consult Clin Psychol 2000; 68(6):947-56

9. Abramowitz JS, Moore EL, Braddock AE, Harrington DL: Self-help cognitive-behavioral therapy with minimal therapist contact for social phobia: a controlled trial. J Behav Ther Exp Psychiatry 2009; 40(1):98-105

10. Addis ME, Hatgis C, Krasnow AD, Jacob K, Bourne L, Mansfield A: Effectiveness of cognitive-behavioral treatment for panic disorder versus treatment as usual in a managed care setting. Journal of Consulting and Clinical Psychology 2004; 72(4):625-635

11. Allgulander C: Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999; 100(3):193-8

12. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G, Group SADS: Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004; 19(6):387-96

13. Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, Kutcher SP, Clary CM: Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004; 161(9):1642-9

14. Andersson G, Paxling B, Roch-Norlund P, Ostman G, Norgren A, Almlov J, Georen L, Breitholtz E, Dahlin M, Cuijpers P, Carlbring P, Silverberg

23

F: Internet-based psychodynamic versus cognitive behavioral guided self-help for generalized anxiety disorder: a randomized controlled trial. Psychother Psychosom 2012; 81(6):344-55

15. Andrews G, Davies M, Titov N: Effectiveness randomized controlled trial of face to face versus Internet cognitive behaviour therapy for social phobia. Aust N Z J Psychiatry 2011; 45(4):337-40

16. Arntz A, van den Hout M: Psychological treatments of panic disorder without agoraphobia: cognitive therapy versus applied relaxation. Behav Res Ther 1996; 34(2):113-21

17. Arntz A: Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder. Behav Res Ther 2003; 41(6):633-46

18. Asakura S, Tajima O, Koyama T: Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2007; 10(2):263-74

19. Asnis GM, Hameedi FA, Goddard AW, Potkin SG, Black D, Jameel M, Desagani K, Woods SW: Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001; 103(1):1-14

20. Bakker A, van Dyck R, Spinhoven P, van Balkom A: Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry 1999; 60(12):831-838

21. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double- blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999; 175:120-6

22. Baldwin DS, Huusom AK, Maehlum E: Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006; 189:264-72

23. Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW: Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005; 66(1):94-9

24. Ballenger JC, Burrows GD, DuPont RL, Jr., Lesser IM, Noyes R, Jr., Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45(5):413-22

25. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155(1):36-42

26. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, Clary CM: Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 2004; 65(3):405-13

27. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010; 13(3):305-20

28. Barlow D, Craske M, Cerny J, Klosko J: Behavioral treatment of panic disorder. Behav Ther 1989; 20:261-82

24

29. Barlow DH, Rapee RM, Brown TA: Behavioral Treatment of Generalized Anxiety Disorder. Behavior Therapy 1992; 23(4):551-570

30. Barlow DH, Gorman JM, Shear MK, Woods SW: Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Jama 2000; 283(19):2529-36

31. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G: Clonazepam in the Treatment of Panic Disorder - a Double-Blind, Placebo-Controlled Trial Investigating the Correlation between Clonazepam Concentrations in Plasma and Clinical-Response. Journal of Clinical Psychopharmacology 1994; 14(2):111-118

32. Beck AT, Sokol L, Clark DA, Berchick R, Wright F: A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry 1992; 149(6):778-83

33. Beck JG, Stanley MA, Baldwin LE, Deagle EA, 3rd, Averill PM: Comparison of cognitive therapy and relaxation training for panic disorder. J Consult Clin Psychol 1994; 62(4):818-26

34. Berger T, Hohl E, Caspar F: Internet-based treatment for social phobia: a randomized controlled trial. J Clin Psychol 2009; 65(10):1021-35

35. Berger T, Caspar F, Richardson R, Kneubuhler B, Sutter D, Andersson G: Internet-based treatment of social phobia: a randomized controlled trial comparing unguided with two types of guided self-help. Behav Res Ther 2011; 49(3):158-69

36. Bergstrom J, Andersson G, Ljotsson B, Ruck C, Andreewitch S, Karlsson A, Carlbring P, Andersson E, Lindefors N: Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial. BMC Psychiatry 2010; 10:54

37. Beutel ME, Scheurich V, Knebel A, Michal M, Wiltink J, Graf-Morgenstern M, Tschan R, Milrod B, Wellek S, Subic-Wrana C: Implementing panic-focused psychodynamic psychotherapy into clinical practice. Can J Psychiatry 2013; 58(6):326-34

38. Bielski RJ, Bose A, Chang CC: A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17(2):65-9

39. Black DW, Wesner R, Bowers W, Gabel J: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50(1):44-50

40. Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, Campeas R, Liebowitz MR: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010; 67(3):286-95

41. Blomhoff S, Tangen Haug T, Hellstrom K, Holme I, Humble M, Madsbu HP, Wold JE: Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179(1):23-30

42. Boettcher J, Berger T, Renneberg B: Does a pre-treatment diagnostic interview affect the outcome of internet-based self-help for social anxiety disorder? a randomized controlled trial. Behav Cogn Psychother 2012; 40(5):513-28

25

43. Bohni MK, Spindler H, Arendt M, Hougaard E, Rosenberg NK: A randomized study of massed three-week cognitive behavioural therapy schedule for panic disorder. Acta Psychiatr Scand 2009; 120(3):187-95

44. Borge FM, Hoffart A, Sexton H, Clark DM, Markowitz JC, McManus F: Residential cognitive therapy versus residential interpersonal therapy for social phobia: a randomized clinical trial. J Anxiety Disord 2008; 22(6):991-1010

45. Borgeat F, Stankovic M, Khazaal Y, Rouget BW, Baumann MC, Riquier F, O'Connor K, Jermann F, Zullino D, Bondolfi G: Does the form or the amount of exposure make a difference in the cognitive-behavioral therapy treatment of social phobia? J Nerv Ment Dis 2009; 197(7):507-13

46. Borkovec TD, Mathews AM, Chambers A, Ebrahimi S, Lytle R, Nelson R: The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety. J Consult Clin Psychol 1987; 55(6):883-8

47. Borkovec TD, Costello E: Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1993; 61(4):611-9

48. Borkovec TD, Newman MG, Pincus AL, Lytle R: A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol 2002; 70(2):288-98

49. Bouchard S, Gauthier J, Laberge B, French D, Pelletier MH, Godbout C: Exposure versus cognitive restructuring in the treatment of panic disorder with agoraphobia. Behav Res Ther 1996; 34(3):213-24

50. Boyer WF, Feighner JP: A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. Int Clin Psychopharmacol 1993; 8(3):173-6

51. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T: Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005; 187:352-9

52. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K: Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67(6):874-81

53. Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E: Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 1998; 155(5):603-9

54. Brown GK, Beck AT, Newman CF, Beck JS, Tran GQ: A comparison of focused and standard cognitive therapy for panic disorder. J Anxiety Disord 1997; 11(3):329-45

55. Butler G, Fennell M, Robson P, Gelder M: Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1991; 59(1):167-75

26

56. Bystritsky A, Rosen RM, Murphy KJ, Bohn P, Keys SA, Vapnik T: Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994; 1(6):287-90

57. Caillard V, Rouillon F, Viel JF, Markabi S: Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group. Acta Psychiatr Scand 1999; 99(1):51-8

58. Carlbring P, Nilsson-Ihrfelt E, Waara J, Kollenstam C, Buhrman M, Kaldo V, Soderberg M, Ekselius L, Andersson G: Treatment of panic disorder: live therapy vs. self-help via the Internet. Behav Res Ther 2005; 43(10):1321-33

59. Carlbring P, Bohman S, Brunt S, Buhrman M, Westling BE, Ekselius L, Andersson G: Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone calls. Am J Psychiatry 2006; 163(12):2119-25

60. Carlbring P, Gunnarsdottir M, Hedensjo L, Andersson G, Ekselius L, Furmark T: Treatment of social phobia: randomised trial of internet-delivered cognitive-behavioural therapy with telephone support. Br J Psychiatry 2007; 190:123-8

61. Castillo A, Sotillo C, Mariategui J: Alprazolam compared to clobazam and placebo in anxious outpatients. Neuropsychobiology 1987; 18(4):189-94

62. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M: A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994; 164(6):759-69

63. Clark DM, Salkovskis PM, Hackmann A, Wells A, Ludgate J, Gelder M: Brief cognitive therapy for panic disorder: A randomized controlled trial. Journal of Consulting and Clinical Psychology 1999; 67(4):583-589

64. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B: Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003; 71(6):1058-67

65. Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J: Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial. J Consult Clin Psychol 2006; 74(3):568-78

66. CNCPS: Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Br J Psychiatry 1992; 160:191-202; discussion 202-5

67. Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Chneiweiss L, Bernard G, Bouvard M: A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 1995; 167(5):635-41

68. Cottraux J, Note I, Albuisson E, Yao SN, Note B, Mollard E, Bonasse F, Jalenques I, Guerin J, Coudert AJ: Cognitive behavior therapy versus supportive therapy in social phobia: a randomized controlled trial. Psychother Psychosom 2000; 69(3):137-46

27

69. Craske MG, Maidenberg E, Bystritsky A: Brief cognitive-behavioral versus nondirective therapy for panic disorder. J Behav Ther Exp Psychiatry 1995; 26(2):113-20

70. Craske MG, DeCola JP, Sachs AD, Pontillo DC: Panic control treatment for agoraphobia. J Anxiety Disord 2003; 17(3):321-33

71. Crits-Christoph P, Newman MG, Rickels K, Gallop R, Gibbons MB, Hamilton JL, Ring-Kurtz S, Pastva AM: Combined medication and cognitive therapy for generalized anxiety disorder. J Anxiety Disord 2011; 25(8):1087-94

72. Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E: A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol 1993; 13(6):429-37

73. Darcis T, Ferreri M, Natens J, Burtin B, Deram P: A multicentre double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety. Human Psychopharmacology: Clinical and Experimental 1995; 10(3):181-187

74. Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH: Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology 1993; 13:423-428

75. Davidson JR, DuPont RL, Hedges D, Haskins JT: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999; 60(8):528-35

76. Davidson JR, Bose A, Korotzer A, Zheng H: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19(4):234-40

77. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM: Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61(10):1005-13

78. Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato LM, van der Hoop RG, Li D: Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24(2):118-25

79. de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R: Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995; 152(5):683-91

80. den Boer JA, Westenberg HG: Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology Berl 1990; 102(1):85-94

81. Dugas MJ, Ladouceur R, Leger E, Freeston MH, Langlois F, Provencher MD, Boisvert JM: Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. J Consult Clin Psychol 2003; 71(4):821-5

82. Dugas MJ, Brillon P, Savard P, Turcotte J, Gaudet A, Ladouceur R, Leblanc R, Gervais NJ: A randomized clinical trial of cognitive-

28

behavioral therapy and applied relaxation for adults with generalized anxiety disorder. Behav Ther 2010; 41(1):46-58

83. Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS: Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986; 47(9):458-60

84. Elie R, Lamontagne Y: Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 1984; 4(3):125-9

85. Enkelmann R: Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1991; 105(3):428-32

86. Fahy TJ, O'Rourke D, Brophy J, Schazmann W, Sciascia S: The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord 1992; 25(1):63-75

87. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC: A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23(3):240-9

88. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R: Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011; 26(4):213-20

89. Ferreri M, Hantouche EG, Billardon M: Interêt de l'hydroxyzine dans le trouble anxiété géneralisée: étude contrôle en double aveugle versus placebo. Encéphale 1994; 20(6):785-91

90. Feske U, Goldstein AJ: Eye movement desensitization and reprocessing treatment for panic disorder: a controlled outcome and partial dismantling study. J Consult Clin Psychol 1997; 65(6):1026-35

91. Fonseca D'El Rey GJFD, Lacavaz JPL, Cejkinski A, Mello SL: Cognitive-behavioral group treatment in social phobia: 12-week outcome. Revista De Psiquiatria Clinica 2008; 35(2):79-83

92. Fontaine R, Annable L, Chouinard G, Ogilvie RI: Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. J Clin Psychopharmacol 1983; 3(2):80-7

93. Fontaine R, Mercier P, Beaudry P, Annable L, Chouinard G: Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand 1986; 74(5):451-8

94. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. Jama 2000; 283(23):3082-8

95. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ: Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991; 48(10):938-45

96. Gloster AT, Wittchen HU, Einsle F, Lang T, Helbig-Lang S, Fydrich T, Fehm L, Hamm AO, Richter J, Alpers GW, Gerlach AL, Strohle A, Kircher T, Deckert J, Zwanzger P, Hofler M, Arolt V: Psychological

29

treatment for panic disorder with agoraphobia: A randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol 2011; 79(3):406-20

97. Gruber K, Moran PJ, Roth WT, Taylor CB: Computer-assisted cognitive behavioral group therapy for social phobia. Behavior Therapy 2001; 32(1):155-165

98. Hackett D, Haudiquet V, Salinas E: A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry 2003; 18(4):182-7

99. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J: Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22(3):167-74

100.Hayes-Skelton SA, Roemer L, Orsillo SM: A Randomized Clinical Trial Comparing an Acceptance-Based Behavior Therapy to Applied Relaxation for Generalized Anxiety Disorder. J Consult Clin Psychol 2013

101.Hedman E, Andersson G, Ljotsson B, Andersson E, Ruck C, Mortberg E, Lindefors N: Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PLoS One 2011; 6(3):e18001

102.Heimberg RG, Dodge CS, Hope DA, Kennedy CR, Zollo LJ, Becker RE: Cognitive Behavioral Group Treatment for Social Phobia - Comparison with a Credible Placebo Control. Cognitive Therapy and Research 1990; 14(1):1-23

103.Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; 55(12):1133-41

104.Hofmann SG: Cognitive mediation of treatment change in social phobia. J Consult Clin Psychol 2004; 72(3):393-9

105.Hoge EA, Bui E, Marques L, Metcalf CA, Morris LK, Robinaugh DJ, Worthington JJ, Pollack MH, Simon NM: Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry 2013

106.Hope DA, Heimberg RG, Bruch MA: Dismantling cognitive-behavioral group therapy for social phobia. Behav Res Ther 1995; 33(6):637-50

107.Hovland A, Nordhus IH, Sjobo T, Gjestad BA, Birknes B, Martinsen EW, Torsheim T, Pallesen S: Comparing Physical Exercise in Groups to Group Cognitive Behaviour Therapy for the Treatment of Panic Disorder in a Randomized Controlled Trial. Behav Cogn Psychother 2012:1-25

108.Hoyer J, Beesdo K, Gloster AT, Runge J, Hofler M, Becker ES: Worry exposure versus applied relaxation in the treatment of generalized anxiety disorder. Psychother Psychosom 2009; 78(2):106-15

109.IMCTGMSP: The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A

30

double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997; 247(2):71-80

110.Ito LM, de Araujo LA, Tess VL, de Barros-Neto TP, Asbahr FR, Marks I: Self-exposure therapy for panic disorder with agoraphobia: randomised controlled study of external v. interoceptive self-exposure. Br J Psychiatry 2001; 178:331-6

111.Jazaieri H, Goldin PR, Werner K, Ziv M, Gross JJ: A Randomized Trial of MBSR Versus Aerobic Exercise for Social Anxiety Disorder. J Clin Psychol 2012

112.Kasper S, Stein DJ, Loft H, Nil R: Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186:222-6

113.Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B: Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24(2):87-96

114.Kenardy JA, Dow MG, Johnston DW, Newman MG, Thomson A, Taylor CB: A comparison of delivery methods of cognitive-behavioral therapy for panic disorder: an international multicenter trial. J Consult Clin Psychol 2003; 71(6):1068-75

115.Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H: A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011; 31(4):418-28

116.Kiropoulos LA, Klein B, Austin DW, Gilson K, Pier C, Mitchell J, Ciechomski L: Is internet-based CBT for panic disorder and agoraphobia as effective as face-to-face CBT? J Anxiety Disord 2008; 22(8):1273-84

117.Klosko JS, Barlow DH, Tassinari R, Cerny JA: A comparison of alprazolam and behavior therapy in treatment of panic disorder. J Consult Clin Psychol 1990; 58(1):77-84

118.Knijnik DZ, Kapczinski F, Chachamovich E, Margis R, Eizirik CL: Psychodynamic group treatment for generalized social phobia. Rev Bras Psiquiatr 2004; 26(2):77-81

119.Knijnik DZ, Blanco C, Salum GA, Moraes CU, Mombach C, Almeida E, Pereira M, Strapasson A, Manfro GG, Eizirik CL: A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry 2008; 23(8):567-74

120.Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ: Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002; 22(3):257-62

121.Kocovski NL, Fleming JE, Hawley LL, Huta V, Antony MM: Mindfulness and acceptance-based group therapy versus traditional cognitive behavioral group therapy for social anxiety disorder: A randomized controlled trial. Behav Res Ther 2013; 51(12):889-98

122.Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM: Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007; 9(2):100-7

31

123.Koszycki D, Benger M, Shlik J, Bradwejn J: Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav Res Ther 2007; 45(10):2518-26

124.Krüger MB, Dahl AA: The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl 1:S19-24

125.Lader M, Scotto JC: A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology-Berl 1998; 139(4):402-6

126.Lader M, Stender K, Burger V, Nil R: Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19(4):241-8

127.Ladouceur R, Dugas MJ, Freeston MH, Leger E, Gagnon F, Thibodeau N: Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. J Consult Clin Psychol 2000; 68(6):957-64

128.Lecrubier Y, Bakker A, Dunbar G, Judge R: A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95(2):145-52

129.Leichsenring F, Salzer S, Jaeger U, Kachele H, Kreische R, Leweke F, Ruger U, Winkelbach C, Leibing E: Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry 2009; 166(8):875-81

130.Leichsenring F, Salzer S, Beutel ME, Herpertz S, Hiller W, Hoyer J, Huesing J, Joraschky P, Nolting B, Poehlmann K, Ritter V, Stangier U, Strauss B, Stuhldreher N, Tefikow S, Teismann T, Willutzki U, Wiltink J, Leibing E: Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: a multicenter randomized controlled trial. Am J Psychiatry 2013; 170(7):759-67

131.Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L: Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004; 65(2):222-9

132.Lidren DM, Watkins PL, Gould RA, Clum GA, Asterino M, Tulloch HL: A comparison of bibliotherapy and group therapy in the treatment of panic disorder. J Consult Clin Psychol 1994; 62(4):865-9

133.Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, Hollander E, Papp L, Goetz D: Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988; 49(7):252-7

134.Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, et al.: Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992; 49(4):290-300

135.Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD: A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002; 63(1):66-74

32

136.Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM: Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64(7):785-92

137.Liebowitz MR, Asnis G, Mangano R, Tzanis E: A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry 2009; 70(4):550-61

138.Liebowitz MR, Gelenberg AJ, Munjack D: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005; 62(2):190-8

139.Liebowitz MR, Mangano RM, Bradwejn J, Asnis G: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005; 66(2):238-47

140.Linden M, Zubraegel D, Baer T, Franke U, Schlattmann P: Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study). Psychother Psychosom 2005; 74(1):36-42

141.Lindsay WR, Gamsu CV, McLaughlin E, Hood EM, Espie CA: A controlled trial of treatments for generalized anxiety. Br J Clin Psychol 1987; 26(Pt 1):3-15

142.Lipsitz JD, Gur M, Vermes D, Petkova E, Cheng J, Miller N, Laino J, Liebowitz MR, Fyer AJ: A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder. Depress Anxiety 2008; 25(6):542-53

143.Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, Sermet E, Servant D: Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002; 63(11):1020-7

144.Loerch B, Graf-Morgenstern M, Hautzinger M, Schlegel S, Hain C, Sandmann J, Benkert O: Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 1999; 174:205-12

145.Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C: Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998; 173:54-60

146.Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R: A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992; 12(2):96-103

147.Marchand A, Roberge P, Primiano S, Germain V: A randomized, controlled clinical trial of standard, group and brief cognitive-behavioral therapy for panic disorder with agoraphobia: a two-year follow-up. J Anxiety Disord 2009; 23(8):1139-47

148.Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, G OS, Lelliott PT, Kirby M, McNamee G, Sengun S, Wickwire K: Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993; 162:776-87

33

149.Mavissakalian M, Michelson L: Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. J Clin Psychiatry 1986; 47(3):117-22

150.Merideth C, Cutler AJ, She F, Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol 2012; 27(1):40-54

151.Mersch PP: The treatment of social phobia: the differential effectiveness of exposure in vivo and an integration of exposure in vivo, rational emotive therapy and social skills training. Behav Res Ther 1995; 33(3):259-69

152.Michelson L, Mavissakalian M, Marchione K: Cognitive, Behavioral, and Psychophysiological Treatments of Agoraphobia - a Comparative Outcome Investigation. Behavior Therapy 1988; 19(2):97-120

153.Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD: Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998; 155(11):1570-7

154.Milrod B, Leon AC, Busch F, Rudden M, Schwalberg M, Clarkin J, Aronson A, Singer M, Turchin W, Klass ET, Graf E, Teres JJ, Shear MK: A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder. Am J Psychiatry 2007; 164(2):265-72

155.Möller HJ, Volz HP, Reimann IW, Stoll KD: Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001; 21(1):59-65

156.Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC: Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67(5):771-82

157.Moroz G, Rosenbaum JF: Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 1999; 60(9):604-12

158.Mörtberg E, Clark DM, Sundin O, Aberg Wistedt A: Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatr Scand 2007; 115(2):142-54

159.Nair NP, Bakish D, Saxena B, Amin M, Schwartz G, West TE: Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 1996; 2(4):192-8

160.Newman MG, Castonguay LG, Borkovec TD, Fisher AJ, Boswell JF, Szkodny LE, Nordberg SS: A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies. J Consult Clin Psychol 2011; 79(2):171-81

161.Nicolini H, Bakish D, Duenas H, Spann M, Erickson J, Hallberg C, Ball S, Sagman D, Russell JM: Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder:

34

examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009; 39(2):267-76

162.Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G: Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol 2004; 19(6):331-6

163.Nordin S, Carlbring P, Cuijpers P, Andersson G: Expanding the limits of bibliotherapy for panic disorder: randomized trial of self-help without support but with a clear deadline. Behav Ther 2010; 41(3):267-76

164.Noyes R, Jr., Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, Hinrichs JV: Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984; 41(3):287-92

165.Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167(3):374-9

166.Oosterbaan D, van Balkom A, Spinhoven P, van Oppen P, van Dyck R: Cognitive therapy versus moclobemide in social phobia: a controlled study. Clin Psychol Psychother. 2001; 8(4):263-73

167.Ost LG, Breitholtz E: Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. Behav Res Ther 2000; 38(8):777-90

168.Ost LG, Westling BE: Applied relaxation vs cognitive behavior therapy in the treatment of panic disorder. Behav Res Ther 1995; 33(2):145-58

169.Ost LG, Westling BE, Hellstrom K: Applied relaxation, exposure in vivo and cognitive methods in the treatment of panic disorder with agoraphobia. Behav Res Ther 1993; 31(4):383-94

170.Ost LG, Thulin U, Ramnero J: Cognitive behavior therapy vs exposure in vivo in the treatment of panic disorder with agoraphobia (corrected from agoraphobia). Behav Res Ther 2004; 42(10):1105-27

171.Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, Liu-Dumaw M: Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160(3):533-40

172.Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24(2):141-9

173.Paxling B, Almlov J, Dahlin M, Carlbring P, Breitholtz E, Eriksson T, Andersson G: Guided internet-delivered cognitive behavior therapy for generalized anxiety disorder: a randomized controlled trial. Cogn Behav Ther 2011; 40(3):159-73

174.Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano GB: Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. J Clin Psychiatry 1990; 51 Suppl:31-9

175.Pohl RB, Feltner DE, Fieve RR, Pande AC: Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-

35

controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25(2):151-8

176.Pollack MH, Worthington JJ, 3rd, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF: Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996; 32(4):667-70

177.Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R: Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998; 55(11):1010-6

178.Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK: Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62(5):350-7

179.Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24(1):1-14

180.Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y: A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 2007; 194(2):233-42

181.Pols H, Zandergen J, de Loof C, Fernandez I, Griez E: Clinical effects of fluvoxamine on panic symptomatology. Acta Psychiatr Belg 1993; 93(3):169-77

182.Power KG, Jerrom DWA, Simpson RJ, Mitchell MJ, Swanson V: A Controlled Comparison of Cognitive Behavior-Therapy, Diazepam and Placebo in the Management of Generalized Anxiety. Behavioural Psychotherapy 1989; 17(1):1-14

183.Power KG, Simpson RJ, Swanson V, Wallace LA: Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Br J Gen Pract 1990; 40(336):289-94

184.Prasko J, Dockery C, Horacek J, Houbova P, Kosova J, Klaschka J, Paskova B, Praskova H, Seifertova D, Zalesky R, Hoschl C: Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett 2006; 27(4):473-81

185.Rapee RM, Gaston JE, Abbott MJ: Testing the efficacy of theoretically derived improvements in the treatment of social phobia. J Consult Clin Psychol 2009; 77(2):317-27

186.Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, Kapczinski F: Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001; 34(10):1303-7

187.Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C: Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 1997; 17(4):272-7

188.Rickels K, Pollack MH, Sheehan DV, Haskins JT: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157(6):968-74

189.Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160(4):749-56

36

190.Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC: Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62(9):1022-30

191.Rickels K, Mangano R, Khan A: A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24(5):488-96

192.Robinson E, Titov N, Andrews G, McIntyre K, Schwencke G, Solley K: Internet treatment for generalized anxiety disorder: a randomized controlled trial comparing clinician vs. technician assistance. PLoS One 2010; 5(6):e10942

193.Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L: Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95(5):444-50

194.Roemer L, Orsillo SM, Salters-Pedneault K: Efficacy of an acceptance-based behavior therapy for generalized anxiety disorder: evaluation in a randomized controlled trial. J Consult Clin Psychol 2008; 76(6):1083-9

195.Salaberria K, Echeburua E: Long-term outcome of cognitive therapy's contribution to self-exposure in vivo to the treatment of generalized social phobia. Behav Modif 1998; 22(3):262-84

196.Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR: Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172:70-7

197.Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK: Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990; 23(2):90-3

198.Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA: Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract 1997; 47(416):150-5

199.Sharp DM, Power KG, Swanson V: Reducing therapist contact in cognitive behaviour therapy for panic disorder and agoraphobia in primary care: global measures of outcome in a randomised controlled trial. Br J Gen Pract 2000; 50(461):963-8

200.Sharp DM, Power KG, Swanson V: A comparison of the efficacy and acceptability of group versus individual cognitive behaviour therapy in the treatment of panic disorder and agoraphobia in primary care. Clinical Psychology & Psychotherapy 2004; 11(2):73-82

201.Shear MK, Pilkonis PA, Cloitre M, Leon AC: Cognitive behavioral treatment compared with nonprescriptive treatment of panic disorder. Arch Gen Psychiatry 1994; 51(5):395-401

202.Sheehan DV, Raj AB, Sheehan KH, Soto S: Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990; 10(1):3-11

203.Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E: The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88(1):1-11

37

204.Sheehan DV, Burnham DB, Iyengar MK, Perera P: Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 2005; 66(1):34-40

205.Smits JA, Powers MB, Buxkamper R, Telch MJ: The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation. Behav Res Ther 2006; 44(12):1773-85

206.Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, Weisler RH, Cutler NR: Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 1996; 57(7):287-91

207.Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64(11):1322-7

208.Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM: Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther 2003; 41(9):991-1007

209.Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM: Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry 2011; 68(7):692-700

210.Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM: Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003; 6(4):317-23

211.Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM: Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005; 177(3):280-8

212.Stein MB, Ron Norton G, Walker JR, Chartier MJ, Graham R: Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. Psychiatry Res 2000; 94(3):191-200

213.Stein DJ, Cameron A, Amrein R, Montgomery SA: Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 2002; 17(4):161-70

214.Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. Jama 1998; 280(8):708-13

215.Stein DJ, Berk M, Els C, Emsley RA, Gittelson L, Wilson D, Oakes R, Hunter B: A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J 1999; 89(4):402-6

216.Swinson RP, Fergus KD, Cox BJ, Wickwire K: Efficacy of telephone-administered behavioral therapy for panic disorder with agoraphobia. Behav Res Ther 1995; 33(4):465-9

217.Telch MJ, Lucas JA, Schmidt NB, Hanna HH, LaNae Jaimez T, Lucas RA: Group cognitive-behavioral treatment of panic disorder. Behav Res Ther 1993; 31(3):279-87

38

218.Telch MJ, Schmidt NB, Jaimez TL, Jacquin KM, Harrington PJ: Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. J Consult Clin Psychol 1995; 63(5):823-30

219.Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, Cohen LS, Spier SA: Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52(2):69-76

220.Tiller JW, Bouwer C, Behnke K: Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl 1:S7-10

221.Titov N, Andrews G, Schwencke G, Drobny J, Einstein D: Shyness 1: distance treatment of social phobia over the Internet. Aust N Z J Psychiatry 2008; 42(7):585-94

222.Titov N, Andrews G, Schwencke G: Shyness 2: treating social phobia online: replication and extension. Aust N Z J Psychiatry 2008; 42(7):595-605

223.Titov N, Andrews G, Choi I, Schwencke G, Mahoney A: Shyness 3: randomized controlled trial of guided versus unguided Internet-based CBT for social phobia. Aust N Z J Psychiatry 2008; 42(12):1030-40

224.Titov N, Andrews G, Robinson E, Schwencke G, Johnston L, Solley K, Choi I: Clinician-assisted Internet-based treatment is effective for generalized anxiety disorder: randomized controlled trial. Australian and New Zealand Journal of Psychiatry 2009; 43(10):905-912

225.Uhlenhuth EH, Matuzas W, Glass RM, Easton C: Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989; 17(3):261-70

226.Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S, Pecknold JC, Hadrava V, Swinson RP: Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158(2):275-81

227.van Apeldoorn FJ, van Hout WJ, Mersch PP, Huisman M, Slaap BR, Hale WW, 3rd, Visser S, van Dyck R, den Boer JA: Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr Scand 2008; 117(4):260-70

228.van Vliet IM, den Boer JA, Westenberg HG: Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994; 115(1-2):128-34

229.Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R: Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161:353-60

230.Vos SP, Huibers MJ, Diels L, Arntz A: A randomized clinical trial of cognitive behavioral therapy and interpersonal psychotherapy for panic disorder with agoraphobia. Psychol Med 2012:1-12

231.Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T: The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170:549-53

232.Wells A, Welford M, King P, Papageorgiou C, Wisely J, Mendel E: A pilot randomized trial of metacognitive therapy vs applied relaxation in the treatment of adults with generalized anxiety disorder. Behav Res Ther 2010; 48(5):429-34

39

233.Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM: A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24(1):49-55

234.Wiborg IM, Dahl AA: Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry 1996; 53(8):689-94

235.Williams SL, Falbo J: Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability. Behav Res Ther 1996; 34(3):253-64

236.Wims E, Titov N, Andrews G, Choi I: Clinician-assisted Internet-based treatment is effective for panic: A randomized controlled trial. Aust N Z J Psychiatry 2010; 44(7):599-607

237.Woelk H, Schläfke S: A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine 2010; 17(2):94-9

download.lww.comdownload.lww.com/wolterskluwer_vitalstream_com/PermaLink/... · Web...

Documents

Transcript of download.lww.comdownload.lww.com/wolterskluwer_vitalstream_com/PermaLink/... · Web...